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NOMENCLATURE AND DESCRIPTION FOR RATING GUIDELINE
RECOMMENDATIONS
Within each recommendation, the strength of recommendation is indicated as Level 1, Level 2, or not graded, and the quality of the
supporting evidence is shown as A, B, C, or D.
ImplicationsGrade*Kidney International SupplementsPatients(2017) 7, 1–59Clinicians PolicyLevel 1
“We recommend”Most people in your situation would
want the recommended course of
action, and only a small proportion
would not.Most patients should receive the
recommended course of action.The recommendation can be
evaluated as a candidate for
developing a policy or a performance
measure.Level 2
“We suggest”The majority of people in your
situation would want the
recommended course of action, but
many would not.Different choices will be appropriate
for different patients. Each patient
needs help to arrive at a management
decision consistent with her or his
values and preferences.The recommendation is likely to
require substantial debate and
involvement of stakeholders before
policy can be determined.*The additional category “not graded” is used, typically, to provide guidance based on common sense or when the topic does not allow adequate application of evidence.
The most common examples include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. The ungraded recommendations
are generally written as simple declarative statements, but are not meant to be interpreted as being stronger recommendations than Level 1 or 2 recommendations.
Grade Quality of evidence MeaningA High We are conﬁdent that the true effect lies close to that of the estimate of the effect.
B Moderate The true effect is likely to be close to the estimate of the effect, but there is a possibility
that it is substantially different.
C Low The true effect may be substantially different from the estimate of the effect.
D Very low The estimate of effect is very uncertain, and often will be far from the truth.7
www.kisupplements.orgCURRENT CHRONIC KIDNEY DISEASE (CKD) NOMENCLATURE USED BY KDIGO
CKD is deﬁned as abnormalities of kidney structure or function, present for > 3 months, with implications for health. CKD is
classiﬁed based on cause, GFR category (G1–G5), and albuminuria category (A1–A3), abbreviated as CGA.Prognosis of CKD by GFR and albuminuria category
Prognosis of CKD by GFR
and albuminuria categories: 
KDIGO 2012
Persistent albuminuria categories,
description and range
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G1 Normal or high ≥90
G2 Mildly decreased 60–89
G3a Mildly to moderately decreased 45–59
G3b Moderately to severely decreased 30–44
G4 Severely decreased 15–29
G5 Kidney failure <15
green, low risk (if no other markers of kidney disease, no CKD); yellow, moderately increased risk; 
orange, high risk; red, very high risk.8 Kidney International Supplements (2017) 7, 1–59
www.kisupplements.orgCONVERSION FACTORS OF CONVENTIONAL UNITS TO SI UNITS
Conventional unit Conversion factor SI unitKidney International Supplements (2017) 7, 1–59Calcium, total mg/dl 0.2495 mmol/l
Calcium, ionized mg/dl 0.25 mmol/l
Creatinine mg/dl 88.4 mmol/l
Parathyroid hormone pg/ml 0.106 pmol/l
Phosphate (inorganic) mg/dl 0.3229 mmol/lNote: conventional unit  conversion factor ¼ SI unit.9
www.kisupplements.orgAbbreviations and acronyms
1,25(OH)2D 1,25-dihydroxyvitamin D
25(OH)D 25-hydroxyvitamin D
AUC area under the curve
bALP bone-speciﬁc alkaline phosphatase
BMD bone mineral density
CAC coronary artery calciﬁcation
CI conﬁdence interval
CT computed tomography
CV coefﬁcient of variation
DXA dual-energy X-ray absorptiometry
eGFR estimated glomerular ﬁltration rate
ERT evidence review team
FGF ﬁbroblast growth factor
FRAX fracture risk assessment tool
GFR glomerular ﬁltration rate
GI gastrointestinal
GRADE Grading of Recommendations Assessment,
Development, and Evaluation
HD hemodialysis
HPT hyperparathyroidism
HR hazard ratio
iPTH intact parathyroid hormone
ISCD International Society of Clinical
Densitometry
ITT intention-to-treat
IU international unit
KDIGO Kidney Disease: Improving Global
Outcomes
KDOQI Kidney Disease Outcomes Quality
Initiative
LVH left ventricular hypertrophy
LVMI left ventricular mass index
MRI magnetic resonance imaging
OR odds ratio
P1NP amino-terminal propeptide of type 1
procollagen
PTH parathyroid hormone
RCT randomized controlled trial
ROC receiver operating characteristic
SD standard deviation
SHPT secondary hyperparathyroidism
VDR vitamin D receptor
10 Kidney International Supplements (2017) 7, 1–59
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SECTION I: USE OF THE CLINICAL PRACTICE GUIDELINE
This Clinical Practice Guideline Update is based upon systematic literature searches last conducted in September 2015 sup-
plemented with additional evidence through February 2017. It is designed to assist decision making. It is not intended to deﬁne
a standard of care, and should not be interpreted as prescribing an exclusive course of management. Variations in practice will
inevitably and appropriately occur when clinicians consider the needs of individual patients, available resources, and limitations
unique to an institution or type of practice. Health care professionals using these recommendations should decide how to apply
them to their own clinical practice.SECTION II: DISCLOSURE
Kidney Disease: Improving Global Outcomes (KDIGO) makes every effort to avoid any actual or reasonably perceived conﬂicts
of interest that may arise from an outside relationship or a personal, professional, or business interest of a member of the Work
Group. All members of the Work Group are required to complete, sign, and submit a disclosure and attestation form showing
all such relationships that might be perceived as or are actual conﬂicts of interest. This document is updated annually, and
information is adjusted accordingly. All reported information is published in its entirety at the end of this document in the
Work Group members’ Biographic and Disclosure section, and is kept on ﬁle at KDIGO.Copyright  2017, KDIGO. Published by Elsevier on behalf of the International Society of Nephrology. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Single copies may be made for personal use as allowed by national copyright laws. Special rates are available for educational
institutions that wish to make photocopies for nonproﬁt educational use. No part of this publication may be reproduced,
amended, or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any
information storage and retrieval system, without explicit permission in writing from KDIGO. Details on how to seek
permission for reproduction or translation, and further information about KDIGO’s permissions policies can be obtained by
contacting Danielle Green, Managing Director, at danielle.green@kdigo.org.
To the fullest extent of the law, neither KDIGO, Kidney International Supplements, nor the authors, contributors, or editors,
assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or
otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.Kidney International Supplements (2017) 7, 1–59 11
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Kidney International Supplements (2017) 7, 1–59; http://dx.doi.org/10.1016/j.kisu.2017.04.001With the growing awareness that chronic kidney disease is an
international health problem, Kidney Disease: Improving
Global Outcomes (KDIGO) was established in 2003 with its
stated mission to “improve the care and outcomes of kidney
disease patients worldwide through promoting coordination,
collaboration, and integration of initiatives to develop and
implement clinical practice guidelines.”
When the KDIGO Clinical Practice Guideline for the
Diagnosis, Evaluation, Prevention, and Treatment of Chronic
Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
was originally published in 2009, the Work Group acknowl-
edged the lack of high-quality evidence on which to base
recommendations. The Guideline included speciﬁc research
recommendations to encourage investigators to help ﬁll the
gaps and bolster the evidence base.
Multiple randomized controlled trials and prospective cohort
studies have been published since the 2009 Guideline, and
therefore KDIGO recognizes the need to reexamine the currency
of all of its guidelines on a periodic basis. Accordingly, KDIGO
convened a Controversies Conference in 2013, titled “CKD-
MBD: Back to the Future,” whose objective was to determine
whether sufﬁcient new data had emerged to support a reassess-
ment of the 2009 CKD-MBD Clinical Practice Guideline and, if
so, to determine the scope of the potential revisions.
Although most of the recommendations were still
considered to be current, the conference identiﬁed a total of
12 recommendations for reevaluation based on new data. In
addition, the conference prepared a table of additional topic
questions to be considered by the guideline update Work
Group. The conference noted that, in spite of the completion
of several key clinical trials since the 2009 publication of the
CKD-MBD guideline, large gaps of knowledge still remained,
as demonstrated by the relatively small number of recom-
mendation statements identiﬁed for reevaluation. Interested12readers should refer to the conference publication for further
details regarding its processes and deliberations.1
Therefore, KDIGO commissioned an update to the CKD-
MBD guideline and formed a Work Group, led by Drs.
Markus Ketteler and Mary Leonard. The Work Group
convened in June 2015 to review and appraise the evidence
accumulated since the 2009 Guideline. The topics addressed
for revision are listed in Table 2 and included issues prompted
by EVOLVE post hoc analyses, which were published after the
2013 Controversies Conference. Though 8 years have passed
since the 2009 CKD-MBD guideline, evidence in many areas
is still lacking, which has resulted in many of the “opinion-
based” recommendation statements from the original guide-
line document remaining unchanged.
In keeping with the standard KDIGO policy of maintain-
ing transparency during the guideline development process
and attesting to its rigor, we conducted an open public review
of the draft CKD-MBD guideline update, and all feedback
received was reviewed and considered by the Work Group
before ﬁnalizing this guideline document for publication. The
comments and suggestions greatly assisted us in shaping a
ﬁnal document that we felt would be as valuable as possible to
the entire nephrology community.
We wish to thank the Work Group co-chairs, Drs. Markus
Ketteler and Mary Leonard, along with all of the Work Group
members, who volunteered countless hours of their time to
develop this guideline. We also thank Dr. Karen Robinson and
her Evidence Review Team at Johns Hopkins University, the
KDIGO staff, and many others for their support that made
this project possible.
David C. Wheeler, MD, FRCP
Wolfgang C. Winkelmayer, MD, MPH, ScD
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www.kisupplements.orgAbstract14The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline
Update for the Diagnosis, Evaluation, Prevention, and Treatment of chronic kidney disease–
mineral and bone disorder (CKD-MBD) represents a selective update of the prior guideline
published in 2009. This update, along with the 2009 publication, is intended to assist the
practitioner caring for adults and children with CKD, those on chronic dialysis therapy, or in-
dividuals with a kidney transplant. Speciﬁcally, the topic areas for which updated recommen-
dations are issued include diagnosis of bone abnormalities in CKD-MBD; treatment of CKD-
MBD by targeting phosphate lowering and calcium maintenance, treatment of abnormalities
in parathyroid hormone in CKD-MBD; treatment of bone abnormalities by antiresorptives and
other osteoporosis therapies; and evaluation and treatment of kidney transplant bone disease.
Development of this guideline update followed an explicit process of evidence review and
appraisal. Treatment approaches and guideline recommendations are based on systematic reviews
of relevant trials, and appraisal of the quality of the evidence and the strength of recommen-
dations followed the GRADE (Grading of Recommendations Assessment, Development,
and Evaluation) approach. Limitations of the evidence are discussed, with areas of future research
also presented.
Keywords: bone abnormalities; bone mineral density; calcium; chronic kidney disease; CKD-
MBD; dialysis; guideline; hyperparathyroidism; hyperphosphatemia; KDIGO; kidney trans-
plantation; mineral and bone disorder; parathyroid hormone; phosphate; phosphorus; systematic
review
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Updated recommendations are denoted in boxes
Chapter 3.1: Diagnosis of CKD-MBD: biochemical abnormalities
3.1.1: We recommend monitoring serum levels of calcium, phosphate, PTH, and alkaline phosphatase activity beginning in
CKD G3a (1C). In children, we suggest such monitoring beginning in CKD G2 (2D).
3.1.2: In patients with CKD G3a–G5D, it is reasonable to base the frequency of monitoring serum calcium,
phosphate, and PTH on the presence and magnitude of abnormalities, and the rate of progression of CKD
(Not Graded).*The 20
begin i
Kidney InReasonable monitoring intervals would be:
 In CKD G3a–G3b: for serum calcium and phosphate, every 6–12 months; and for PTH, based on baseline level and
CKD progression.
 In CKD G4: for serum calcium and phosphate, every 3–6 months; and for PTH, every 6–12 months.
 In CKD G5, including G5D: for serum calcium and phosphate, every 1–3 months; and for PTH, every 3–6
months.
 In CKD G4–G5D: for alkaline phosphatase activity, every 12 months, or more frequently in the presence of
elevated PTH (see Chapter 3.2).
In CKD patients receiving treatments for CKD-MBD, or in whom biochemical abnormalities are identiﬁed, it is
reasonable to increase the frequency of measurements to monitor for trends and treatment efﬁcacy and side effects
(Not Graded).3.1.3: In patients with CKD G3a–G5D, we suggest that 25(OH)D (calcidiol) levels might be measured, and repeated testing
determined by baseline values and therapeutic interventions (2C). We suggest that vitamin D deﬁciency and
insufﬁciency be corrected using treatment strategies recommended for the general population (2C).
3.1.4: In patients with CKD G3a–G5D, we recommend that therapeutic decisions be based on trends rather than on a
single laboratory value, taking into account all available CKD-MBD assessments (1C).
3.1.5: In patients with CKD G3a–G5D, we suggest that individual values of serum calcium and phosphate, evaluated
together, be used to guide clinical practice rather than the mathematical construct of calcium-phosphate product
(Ca 3 P) (2D).
3.1.6: In reports of laboratory tests for patients with CKD G3a–G5D, we recommend that clinical laboratories inform
clinicians of the actual assay method in use and report any change in methods, sample source (plasma or serum), or
handling speciﬁcations to facilitate the appropriate interpretation of biochemistry data (1B).
Chapter 3.2: Diagnosis of CKD-MBD: bone
3.2.1: In patients with CKD G3a–G5D with evidence of CKD-MBD and/or risk factors for osteoporosis, we suggest
BMD testing to assess fracture risk if results will impact treatment decisions (2B).
3.2.2: In patients with CKD G3a–G5D, it is reasonable to perform a bone biopsy if knowledge of the type of renal
osteodystrophy will impact treatment decisions (Not Graded).
3.2.3: In patients with CKD G3a–G5D, we suggest that measurements of serum PTH or bone-speciﬁc alkaline
phosphatase can be used to evaluate bone disease because markedly high or low values predict underlying
bone turnover (2B).
3.2.4: In patients with CKD G3a–G5D, we suggest not to routinely measure bone-derived turnover markers of collagen
synthesis (such as procollagen type I C-terminal propeptide) and breakdown (such as type I collagen cross-linked
telopeptide, cross-laps, pyridinoline, or deoxypyridinoline) (2C).09 Guideline Chapters 1 and 2 provide the Introduction and Methodological Approach, respectively, and therefore guideline recommendations
n Chapter 3.1.
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summary of recommendation statements www.kisupplements.org3.2.5: We recommend that infants with CKD G2–G5D have their length measured at least quarterly, while children with
CKD G2–G5D should be assessed for linear growth at least annually (1B).
Chapter 3.3: Diagnosis of CKD-MBD: vascular calciﬁcation
3.3.1: In patients with CKD G3a–G5D, we suggest that a lateral abdominal radiograph can be used to detect the presence or
absence of vascular calciﬁcation, and an echocardiogram can be used to detect the presence or absence of valvular
calciﬁcation, as reasonable alternatives to computed tomography-based imaging (2C).
3.3.2: We suggest that patients with CKD G3a–G5D with known vascular or valvular calciﬁcation be considered at
highest cardiovascular risk (2A). It is reasonable to use this information to guide the management of CKD-MBD
(Not Graded).
Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphate and maintaining
serum calcium
4.1.1: In patients with CKD G3a–G5D, treatments of CKD-MBD should be based on serial assessments of phosphate,
calcium, and PTH levels, considered together (Not Graded).
4.1.2: In patients with CKD G3a–G5D, we suggest lowering elevated phosphate levels toward the normal range (2C).
4.1.3: In adult patients with CKD G3a–G5D, we suggest avoiding hypercalcemia (2C). In children with CKD G3a–G5D,
we suggest maintaining serum calcium in the age-appropriate normal range (2C).
4.1.4: In patients with CKD G5D, we suggest using a dialysate calcium concentration between 1.25 and 1.50 mmol/l
(2.5 and 3.0 mEq/l) (2C).
4.1.5: In patients with CKD G3a-G5D, decisions about phosphate-lowering treatment should be based on progressively
or persistently elevated serum phosphate (Not Graded).
4.1.6: In adult patients with CKD G3a–G5D receiving phosphate-lowering treatment, we suggest restricting the dose of
calcium-based phosphate binders (2B). In children with CKD G3a–G5D, it is reasonable to base the choice of
phosphate-lowering treatment on serum calcium levels (Not Graded).
4.1.7: In patients with CKD G3a-G5D, we recommend avoiding the long-term use of aluminum-containing phosphate
binders and, in patients with CKD G5D, avoiding dialysate aluminum contamination to prevent aluminum
intoxication (1C).
4.1.8: In patients with CKD G3a–G5D, we suggest limiting dietary phosphate intake in the treatment of hyper-
phosphatemia alone or in combination with other treatments (2D). It is reasonable to consider phosphate source
(e.g., animal, vegetable, additives) in making dietary recommendations (Not Graded).
4.1.9: In patients with CKD G5D, we suggest increasing dialytic phosphate removal in the treatment of persistent
hyperphosphatemia (2C).
Chapter 4.2: Treatment of abnormal PTH levels in CKD-MBD
4.2.1: In patients with CKD G3a–G5 not on dialysis, the optimal PTH level is not known. However, we suggest that
patients with levels of intact PTH progressively rising or persistently above the upper normal limit for the assay
be evaluated for modiﬁable factors, including hyperphosphatemia, hypocalcemia, high phosphate intake, and
vitamin D deﬁciency (2C).
4.2.2: In adult patients with CKD G3a–G5 not on dialysis, we suggest that calcitriol and vitamin D analogs not be
routinely used (2C). It is reasonable to reserve the use of calcitriol and vitamin D analogs for patients with CKD
G4–G5 with severe and progressive hyperparathyroidism (Not Graded).
In children, calcitriol and vitamin D analogs may be considered to maintain serum calcium levels in the
age-appropriate normal range (Not Graded).16 Kidney International Supplements (2017) 7, 1–59
www.kisupplements.org summary of recommendation statements4.2.3: In patients with CKD G5D, we suggest maintaining iPTH levels in the range of approximately 2 to 9 times the upper
normal limit for the assay (2C).Kidney IWe suggest that marked changes in PTH levels in either direction within this range prompt an initiation or change in
therapy to avoid progression to levels outside of this range (2C).4.2.4: In patients with CKD G5D requiring PTH-lowering therapy, we suggest calcimimetics, calcitriol, or vitamin D
analogs, or a combination of calcimimetics with calcitriol or vitamin D analogs (2B).
4.2.5: In patients with CKD G3a–G5D with severe hyperparathyroidism (HPT) who fail to respond to medical or phar-
macological therapy, we suggest parathyroidectomy (2B).
Chapter 4.3: Treatment of bone with bisphosphonates, other osteoporosis medications, and
growth hormone
4.3.1: In patients with CKD G1–G2 with osteoporosis and/or high risk of fracture, as identiﬁed by World Health Orga-
nization criteria, we recommend management as for the general population (1A).
4.3.2: In patients with CKD G3a–G3b with PTH in the normal range and osteoporosis and/or high risk of fracture, as
identiﬁed by World Health Organization criteria, we suggest treatment as for the general population (2B).
4.3.3: In patients with CKD G3a–G5D with biochemical abnormalities of CKD-MBD and low BMD and/or fragility
fractures, we suggest that treatment choices take into account the magnitude and reversibility of the biochemical
abnormalities and the progression of CKD, with consideration of a bone biopsy (2D).
4.3.4: In children and adolescents with CKD G2–G5D and related height deﬁcits, we recommend treatment with re-
combinant human growth hormone when additional growth is desired, after ﬁrst addressing malnutrition and
biochemical abnormalities of CKD-MBD (1A).
Chapter 5: Evaluation and treatment of kidney transplant bone disease
5.1: In patients in the immediate post–kidney transplant period, we recommend measuring serum calcium and phosphate
at least weekly, until stable (1B).
5.2: In patients after the immediate post–kidney transplant period, it is reasonable to base the frequency of monitoring
serum calcium, phosphate, and PTH on the presence and magnitude of abnormalities, and the rate of progression of
CKD (Not Graded).Reasonable monitoring intervals would be:
 In CKD G1T–G3bT, for serum calcium and phosphate, every 6–12 months; and for PTH, once, with subsequent
intervals depending on baseline level and CKD progression.
 In CKD G4T, for serum calcium and phosphate, every 3–6 months; and for PTH, every 6–12 months.
 In CKD G5T, for serum calcium and phosphate, every 1–3 months; and for PTH, every 3–6 months.
 In CKD G3aT–G5T, measurement of alkaline phosphatases annually, or more frequently in the presence of elevated
PTH (see Chapter 3.2).In CKD patients receiving treatments for CKD-MBD, or in whom biochemical abnormalities are identiﬁed, it is
reasonable to increase the frequency of measurements to monitor for efﬁcacy and side effects (Not Graded).
It is reasonable to manage these abnormalities as for patients with CKD G3a–G5 (see Chapters 4.1 and 4.2)
(Not Graded).
5.3: In patients with CKD G1T–G5T, we suggest that 25(OH)D (calcidiol) levels might be measured, and repeated testing
determined by baseline values and interventions (2C).
5.4: In patients with CKD G1T–G5T, we suggest that vitamin D deﬁciency and insufﬁciency be corrected using treatment
strategies recommended for the general population (2C).nternational Supplements (2017) 7, 1–59 17
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15.5: In patients with CKD G1T–G5T with risk factors for osteoporosis, we suggest that BMD testing be used to assess
fracture risk if results will alter therapy (2C).
5.6: In patients in the ﬁrst 12 months after kidney transplant with an estimated glomerular ﬁltration rate greater than
approximately 30 ml/min/1.73 m2 and low BMD, we suggest that treatment with vitamin D, calcitriol/alfacalcidol,
and/or antiresorptive agents be considered (2D).8 We suggest that treatment choices be inﬂuenced by the presence of CKD-MBD, as indicated by abnormal levels
of calcium, phosphate, PTH, alkaline phosphatases, and 25(OH)D (2C).
 It is reasonable to consider a bone biopsy to guide treatment (Not Graded).
There are insufﬁcient data to guide treatment after the ﬁrst 12 months.5.7: In patients with CKD G4T–G5T with known low BMD, we suggest management as for patients with CKD G4–G5 not
on dialysis, as detailed in Chapters 4.1 and 4.2 (2C).
The 2017 updated recommendations resulted in renumbering of several adjacent guideline statements. Speciﬁcally, 2009
Recommendation 4.1.6 now becomes 2017 Recommendation 4.1.7; 2009 Recommendation 4.1.8 now becomes 2017
Recommendation 4.1.9; 2009 Recommendation 4.3.5 now becomes 2017 Recommendation 4.3.4; and 2009 Recommen-
dation 5.8 now becomes 2017 Recommendation 5.7.Kidney International Supplements (2017) 7, 1–59
www.kisupplements.orgSummary and comparison of 2017 updated and 2009
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3.2.1. In patients with CKD G3a–G5D with
evidence of CKD-MBD and/or risk factors for
osteoporosis, we suggest BMD testing to
assess fracture risk if results will impact
treatment decisions (2B).
3.2.2. In patients with CKD G3a–G5D with evidence
of CKD-MBD, we suggest that BMD testing not be
performed routinely, because BMD does not
predict fracture risk as it does in the general
population, and BMD does not predict the type of
renal osteodystrophy (2B).
Multiple new prospective studies have
documented that lower DXA BMD predicts
incident fractures in patients with CKD G3a–
G5D. The order of these ﬁrst 2
recommendations was changed because a
DXA BMD result might impact the decision to
perform a bone biopsy.
3.2.2. In patients with CKD G3a–G5D, it is
reasonable to perform a bone biopsy if
knowledge of the type of renal osteodystrophy
will impact treatment decisions (Not Graded).
3.2.1. In patients with CKD G3a–G5D, it is
reasonable to perform a bone biopsy in various
settings including, but not limited to: unexplained
fractures, persistent bone pain, unexplained
hypercalcemia, unexplained hypophosphatemia,
possible aluminum toxicity, and prior to therapy
with bisphosphonates in patients with CKD-MBD
(Not Graded).
The primary motivation for this revision was
the growing experience with osteoporosis
medications in patients with CKD, low BMD,
and a high risk of fracture. The inability to
perform a bone biopsy may not justify
withholding antiresorptive therapy from
patients at high risk of fracture.
4.1.1. In patients with CKD G3a–G5D,
treatments of CKD-MBD should be based on
serial assessments of phosphate, calcium, and
PTH levels, considered together (Not Graded).
This new recommendation was provided in
order to emphasize the complexity and
interaction of CKD-MBD laboratory parameters.
4.1.2. In patients with CKD G3a–G5D, we
suggest lowering elevated phosphate levels
toward the normal range (2C).
4.1.1. In patients with CKD G3a–G5, we suggest
maintaining serum phosphate in the normal
range (2C). In patients with CKD G5D, we suggest
lowering elevated phosphate levels toward the
normal range (2C).
There is an absence of data supporting that
efforts to maintain phosphate in the normal
range are of beneﬁt to CKD G3a–G4 patients,
including some safety concerns. Treatment
should aim at overt hyperphosphatemia.
4.1.3. In adult patients with CKD G3a–G5D, we
suggest avoiding hypercalcemia (2C).
In children with CKD G3a–G5D, we suggest
maintaining serum calcium in the age-
appropriate normal range (2C).
4.1.2. In patients with CKD G3a–G5D, we suggest
maintaining serumcalcium in the normal range (2D).
Mild and asymptomatic hypocalcemia (e.g., in
the context of calcimimetic treatment) can be
tolerated in order to avoid inappropriate
calcium loading in adults.
4.1.4. In patients with CKD G5D, we suggest
using a dialysate calcium concentration
between 1.25 and 1.50 mmol/l (2.5 and 3.0
mEq/l) (2C).
4.1.3. In patients with CKD G5D, we suggest using
a dialysate calcium concentration between 1.25
and 1.50 mmol/l (2.5 and 3.0 mEq/l) (2D).
Additional studies of better quality are
available; however, these do not allow for
discrimination of beneﬁts and harms between
calcium dialysate concentrations of 1.25 and
1.50 mmol/l (2.5 and 3.0 mEq/l). Hence, the
wording is unchanged, but the evidence grade
is upgraded from 2D to 2C.
4.1.5. In patients with CKD G3a–G5D, decisions
about phosphate-lowering treatment should
be based on progressively or persistently
elevated serum phosphate (Not Graded).
4.1.4. In patients with CKD G3a–G5 (2D) and G5D
(2B), we suggest using phosphate-binding agents
in the treatment of hyperphosphatemia. It is
reasonable that the choice of phosphate binder
takes into account CKD stage, presence of other
components of CKD-MBD, concomitant therapies,
and side effect proﬁle (Not Graded).
Emphasizes the perception that early
“preventive” phosphate-lowering treatment is
currently not supported by data (see
Recommendation 4.1.2).
The broader term “phosphate-lowering”
treatment is used instead of phosphate
binding agents since all possible approaches
(i.e., binders, diet, dialysis) can be effective.
(Continued on next page)
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4.1.6. In adult patients with CKD G3a–G5D
receiving phosphate-lowering treatment, we
suggest restricting the dose of calcium-based
phosphate binder (2B). In children with CKD
G3a–G5D, it is reasonable to base the choice of
phosphate-lowering treatment on serum
calcium levels (Not Graded).
4.1.5. In patients with CKD G3a–G5D and
hyperphosphatemia, we recommend restricting
the dose of calcium-based phosphate binders
and/or the dose of calcitriol or vitamin D analog in
the presence of persistent or recurrent
hypercalcemia (1B).
New evidence from 3 RCTs supports a more
general recommendation to restrict calcium-
based phosphate binders in
hyperphosphatemic patients across all
severities of CKD.
In patients with CKD G3a–G5D and
hyperphosphatemia, we suggest restricting the
dose of calcium-based phosphate binders in the
presence of arterial calciﬁcation (2C) and/or
adynamic bone disease (2C) and/or if serum PTH
levels are persistently low (2C).
4.1.8. In patients with CKD G3a–G5D, we
suggest limiting dietary phosphate intake in
the treatment of hyperphosphatemia alone or
in combination with other treatments (2D). It is
reasonable to consider phosphate source (e.g.,
animal, vegetable, additives) in making dietary
recommendations (Not Graded).
4.1.7. In patients with CKD G3a–G5D, we suggest
limiting dietary phosphate intake in the treatment
of hyperphosphatemia alone or in combination
with other treatments (2D).
New data on phosphate sources were deemed
to be included as an additional qualiﬁer to the
previous recommendation.
4.2.1. In patients with CKD G3a–G5 not on
dialysis, the optimal PTH level is not known.
However, we suggest that patients with levels
of intact PTH progressively rising or
persistently above the upper normal limit for
the assay be evaluated for modiﬁable factors,
including hyperphosphatemia, hypocalcemia,
high phosphate intake, and vitamin D
deﬁciency (2C).
4.2.1. In patients with CKD G3a–G5 not on dialysis,
the optimal PTH level is not known. However, we
suggest that patients with levels of intact PTH
above the upper normal limit of the assay are ﬁrst
evaluated for hyperphosphatemia, hypocalcemia,
and vitamin D deﬁciency (2C).
It is reasonable to correct these abnormalities with
any or all of the following: reducing dietary
phosphate intake and administering phosphate
binders, calcium supplements, and/or native
vitamin D (Not Graded).
The Work Group felt that modest increases in
PTH may represent an appropriate adaptive
response to declining kidney function and has
revised this statement to include “persistently”
above the upper normal PTH level as well as
“progressively rising” PTH levels, rather than
“above the upper normal limit.” That is,
treatment should not be based on a single
elevated value.
4.2.2. In adult patients with CKD G3a–G5 not on
dialysis, we suggest that calcitriol and vitamin D
analogs not be routinely used. (2C) It is
reasonable to reserve the use of calcitriol and
vitamin D analogs for patients with CKD G4–G5
with severe and progressive
hyperparathyroidism (Not Graded).
4.2.2. In patients with CKD G3a–G5 not on dialysis,
in whom serum PTH is progressively rising and
remains persistently above the upper limit of
normal for the assay despite correction of
modiﬁable factors, we suggest treatment with
calcitriol or vitamin D analogs (2C).
Recent RCTs of vitamin D analogs failed to
demonstrate improvements in clinically
relevant outcomes but demonstrated
increased risk of hypercalcemia.
In children, calcitriol and vitamin D analogs
may be considered to maintain serum calcium
levels in the age-appropriate normal range
(Not Graded).
4.2.4. In patients with CKD G5D requiring PTH-
lowering therapy, we suggest calcimimetics,
calcitriol, or vitamin D analogs, or a
combination of calcimimetics with calcitriol or
vitamin D analogs (2B).
4.2.4. In patients with CKD G5D and elevated or
rising PTH, we suggest calcitriol, or vitamin D
analogs, or calcimimetics, or a combination of
calcimimetics and calcitriol or vitamin D analogs
be used to lower PTH (2B).
 It is reasonable that the initial drug selection for
the treatment of elevated PTH be based on
serum calcium and phosphate levels and other
aspects of CKD-MBD (Not Graded).
 It is reasonable that calciumornon-calcium-based
phosphate binder dosage be adjusted so that
treatments to control PTH do not compromise
levels of phosphate and calcium (Not Graded).
 We recommend that, in patients with hyper-
calcemia, calcitriol or another vitamin D sterol
be reduced or stopped (1B).
This recommendation originally had not been
suggested for updating by the KDIGO
Controversies Conference in 2013. However,
due to a subsequent series of secondary and
post hoc publications of the EVOLVE trial, the
Work Group decided to reevaluate
Recommendation 4.2.4 as well. Although
EVOLVE did not meet its primary endpoint, the
majority of the Work Group members were
reluctant to exclude potential beneﬁts of
calcimimetics for G5D patients based on
subsequent prespeciﬁed analyses. The Work
Group, however, decided not to prioritize any
PTH-lowering treatment at this time because
calcimimetics, calcitriol, or vitamin D analogs
are all acceptable ﬁrst-line options in G5D
patients.
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 We suggest that, in patients with hyper-
phosphatemia, calcitriol or another vitamin D
sterol be reduced or stopped (2D).
 We suggest that, in patients with hypocalcemia,
calcimimetics be reduced or stopped depend-
ing on severity, concomitant medications, and
clinical signs and symptoms (2D).
 We suggest that, if the intact PTH levels fall
below 2 times the upper limit of normal for the
assay, calcitriol, vitamin D analogs, and/or cal-
cimimetics be reduced or stopped (2C).
4.3.3. In patients with CKD G3a–G5D with
biochemical abnormalities of CKD-MBD and
low BMD and/or fragility fractures, we suggest
that treatment choices take into account the
magnitude and reversibility of the biochemical
abnormalities and the progression of CKD,
with consideration of a bone biopsy (2D).
4.3.3. In patients with CKD G3a–G3b with
biochemical abnormalities of CKD-MBD and low
BMD and/or fragility fractures, we suggest that
treatment choices take into account the
magnitude and reversibility of the biochemical
abnormalities and the progression of CKD, with
consideration of a bone biopsy (2D).
Recommendation 3.2.2 now addresses the
indications for a bone biopsy prior to
antiresorptive and other osteoporosis
therapies. Therefore, 2009 Recommendation
4.3.4 has been removed and 2017
Recommendation 4.3.3 is broadened from CKD
G3a–G3b to CKD G3a–G5D.
4.3.4. In patients with CKD G4–G5D having
biochemical abnormalities of CKD-MBD, and low
BMD and/or fragility fractures, we suggest
additional investigation with bone biopsy prior to
therapy with antiresorptive agents (2C).
5.5. In patients with G1T–G5T with risk factors
for osteoporosis, we suggest that BMD testing
be used to assess fracture risk if results will
alter therapy (2C).
5.5. In patients with an estimated glomerular
ﬁltration rate greater than approximately 30 ml/
min/1.73 m2, we suggest measuring BMD in the
ﬁrst 3 months after kidney transplant if they
receive corticosteroids, or have risk factors for
osteoporosis as in the general population (2D).
2009 Recommendations 5.5 and 5.7 were
combined to yield 2017 Recommendation 5.5.
5.7. In patients with CKD G4T–G5T, we suggest
that BMD testing not be performed routinely,
because BMD does not predict fracture risk as it
does in the general population and BMD does
not predict the type of kidney transplant bone
disease (2B).
5.6. In patients in the ﬁrst 12 months after
kidney transplant with an estimated
glomerular ﬁltration rate greater than
approximately 30 ml/min/1.73 m2 and low
BMD, we suggest that treatment with vitamin
D, calcitriol/alfacalcidol, and/or antiresorptive
agents be considered (2D).
 We suggest that treatment choices be
inﬂuenced by the presence of CKD-MBD, as
indicated by abnormal levels of calcium,
phosphate, PTH, alkaline phosphatases, and
25(OH)D (2C).
 It is reasonable to consider a bone biopsy to
guide treatment (Not Graded).
There are insufﬁcient data to guide treatment
after the ﬁrst 12 months.
5.6. In patients in the ﬁrst 12 months after kidney
transplant with an estimated glomerular ﬁltration
rate greater than approximately 30 ml/min/1.73
m2 and low BMD, we suggest that treatment with
vitamin D, calcitriol/alfacalcidol, or
bisphosphonates be considered (2D).
 We suggest that treatment choices be inﬂu-
enced by the presence of CKD-MBD, as indi-
cated by abnormal levels of calcium, phosphate,
PTH, alkaline phosphatases, and 25(OH)D (2C).
 It is reasonable to consider a bone biopsy to
guide treatment, speciﬁcally before the use of
bisphosphonates due to the high incidence of
adynamic bone disease (Not Graded).
There are insufﬁcient data to guide treatment after
the ﬁrst 12 months.
The second bullet is revised, consistent with
the new bone biopsy recommendation (i.e.,
2017 Recommendation 3.2.2).
25(OH)D, 25-hydroxyvitamin D; BMD, bone mineral density; CKD, chronic kidney disease; CKD-MBD, chronic kidney disease–mineral bone disorder; DXA, dual-energy x-ray
absorptiometry; PTH, parathyroid hormone; RCT, randomized controlled trial.
Changes to above summarized recommendations resulted in renumbering of several adjacent guideline statements. Speciﬁcally, 2009 Recommendation 4.1.6 now becomes
2017 Recommendation 4.1.7; 2009 Recommendation 4.1.8 now becomes 2017 Recommendation 4.1.9; 2009 Recommendation 4.3.5 now becomes 2017 Recommendation
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chap te r 3 . 2 www.kisupplements.orgChapter 3.2: Diagnosis of CKD-MBD: bone3.2.1: In patients with CKD G3a–G5D with evidence of
CKD-MBD and/or risk factors for osteoporosis, we
suggest BMD testing to assess fracture risk if results
will impact treatment decisions (2B).
Rationale
It is well established that patients with CKD G3a–G5D have
increased fracture rates compared with the general popula-
tion,2–4 and moreover, incident hip fractures are associated
with substantial morbidity and mortality.5–9 At the time of
the 2009 KDIGO CKD-MBD guideline, publications
addressing the ability of dual-energy X-ray absorptiometry
(DXA) measures of bone mineral density (BMD) to estimate
fracture risk in CKD were limited to cross-sectional studies
comparing BMD in CKD patients with and without a prev-
alent fracture. The results were variable across studies and
across skeletal sites. In light of the lack of evidence that DXA
BMD predicted fractures in CKD patients as it does in the
general population, and the inability of DXA to indicate the
histological type of bone disease, the 2009 Guideline recom-
mended that BMD testing not be performed routinely in
patients with CKD G3a to G5D with CKD-MBD. Further-
more, the lack of clinical trials in patients with low BMD and
CKD also limited the enthusiasm for measuring BMD in the
ﬁrst place.
The current evidence-based review identiﬁed 4 prospective
cohort studies of DXA BMD and incident fractures in adults
with CKD G3a to G5D (Supplementary Tables S7–S12).
These studies demonstrated that DXA BMD predicted frac-
tures across the spectrum from CKD G3a to G5D
(Supplementary Tables S7–S12).10–13 In the earliest study,
DXA BMD was measured annually in 485 hemodialysis (HD)
patients (mean age: 60 years) in a single center in Japan.10 In
adjusted Cox proportional analyses, lower baseline femoral
neck and total hip BMD predicted a greater risk of fracture;
for example, the hazard ratio (HR) was 0.65 (95% conﬁdence
interval [CI]: 0.47–0.90) for each standard deviation (SD)
higher femoral neck BMD. In receiver operating characteristic
(ROC) analyses stratiﬁed according to parathyroid hormone
(PTH) below or above the median value of 204 pg/ml (21.6
pmol/l), the area under the curve (AUC) for femoral neck
BMD was 0.717 in the lower stratum and 0.512 in the higher
stratum. Of note, higher serum bone-speciﬁc alkaline phos-
phate levels also predicted incident fractures.
In the second study, Yenchek et al. assessed whether DXA
total hip and femoral neck BMD were associated with incident
nonspine fragility fractures in participants with estimated
glomerular ﬁltration rate (eGFR) < 60 ml/min/1.73 m2 and22without CKD in the Health, Aging and Body Composition
Study, a prospective study of community-living individuals, 70
to 79 years of age at enrollment.13 A total of 587 (21%) of the
2754 participants had CKD, and among those, 83% and 13%
had CKD G3a and G3b, respectively. In adjusted analyses, the
fracture HR for each SD lower femoral neck BMD was 2.14
(95% CI: 1.80–2.55) in participants without CKD, and 2.69
(95% CI: 1.96–3.69) in those with CKD. Similar results were
observed for total hip BMD.When limited to hip fractures, the
adjusted femoral neck BMD HRs were 5.82 (95% CI: 3.27–
10.35) among those with CKD and 3.08 (95% CI: 2.29–4.14)
among those without CKD. Interaction terms demonstrated
that the association of BMDwith fracture did not differ in those
with versus without CKD. However, the association of femoral
neck BMDwith fracture was signiﬁcantly less pronounced (test
for interaction, P ¼ 0.04) among those with PTH > 65 pg/ml
(6.9 pmol/l; HR: 1.56, 95%CI: 0.90–2.70) comparedwith those
with a PTH # 65 pg/ml (6.9 pmol/l; HR: 2.41, 95% CI: 2.04–
2.85) in all participants combined. This is noteworthy in light
of the similar pattern observed in dialysis patients, as described
above.10
West et al. reported the results of a prospective cohort
study of 131 predialysis participants, mean age 62 years, fol-
lowed up over a 2-year interval.12 At baseline, the proportions
with CKD G3a to G3b, G4, and G5 were 34%, 40%, and 26%,
respectively. DXA BMD was measured in the total hip, lum-
bar spine, and ultradistal and one-third radius at baseline and
2 years. Low BMD at all sites, and a greater annualized per-
centage decrease in BMD predicted fracture. For example, in
multivariate models, each SD lower total hip BMD was
associated with an odds ratio (OR) of fracture of 1.75 (95%
CI: 1.30–2.20). The ROC AUC ranged from 0.62 in the spine
to 0.74 in the ultradistal radius in adjusted models.
Most recently, Naylor, et al.11 assessed the ability of the
Fracture Risk Assessment Tool (FRAX) to predict a major
osteoporotic fracture in 2107 adults $ 40 years of age in the
Canadian Multicenter Osteoporosis Study, including 320 with
an eGFR # 60 ml/min/1.73 m2. Of these, 72% and 24% had
CKD G3a and G3b, respectively. FRAX with BMD, FRAX
without BMD, and the femoral neck T-score all predicted
fractures (AUC: 0.65 to 0.71); the AUC was highest for femoral
neck T-score with inclusion of fall history. Importantly, the
AUCs did not differ between those with and without CKD.
There is growing evidence that DXA BMD predicts frac-
tures in healthy children and adolescents, and those with
chronic disease.14,15 However, no studies have examined the
associations among DXA BMD and fractures in children and
adolescents with CKD. In light of the lack of evidence that theKidney International Supplements (2017) 7, 1–59
www.kisupplements.org chap te r 3 . 2ability of DXA BMD to predict fracture in children with CKD
is different than in adults, no speciﬁc recommendations are
provided for children. However, it should be noted that
children and adolescents with CKD frequently exhibit sub-
stantial growth failure. Given that DXA measures of areal
BMD (g/cm2) underestimate volumetric BMD (g/cm3) in
children with short stature,16 DXA results should be adjusted
for bone size, consistent with the 2013 International Society
of Clinical Densitometry (ISCD) Pediatric Ofﬁcial Posi-
tions.17 Prediction equations to adjust DXA results for height
Z-score are now available,16 and the impact on DXA BMD
Z-scores in childrenwith CKD is substantial.18 Finally, a single-
center study in 171 children with CKD G2 to G5D reported
that lower cortical volumetric BMD in the tibia, as measured
by peripheral quantitative computed tomography (CT), pre-
dicted fractures over a 1-year interval (Supplementary
Tables S7–S12).19 The HR per unit lower cortical BMD
Z-score was 1.75 (95% CI: 1.15–2.67; P < 0.01).
The evidence-based review also evaluated clinical trials of
the effects of osteoporosis medications on BMD in CKD G3a
to G5D (Supplementary Tables S1–S6). Prior analyses of large
randomized clinical trials (RCTs) evaluating medications for
the treatment of postmenopausal osteoporosis (risedronate,
alendronate, teriparatide, and raloxifene) were described in
the 2009 Guideline. These trials speciﬁcally excluded patients
with an elevated serum creatinine, hyperparathyroidism, or
abnormal alkaline phosphate levels (i.e., CKD-MBD).20–23
However, post hoc analyses found that these drugs had
similar efﬁcacy on improving BMD and reducing fracture
incidence in individuals with moderately reduced eGFR,
compared with those with mildly decreased or normal eGFR.
Three new trials were identiﬁed. The denosumab study was
also a post hoc analysis of an RCT in women with post-
menopausal osteoporosis and normal PTH levels.24 The
analysis demonstrated efﬁcacy of denosumab in decreasing
fracture risk and increasing BMD in 2817 women with CKD
G3a to G3b and 73 with CKD G4. Here, the risk of hypo-
calcemia associated with denosumab in advanced CKD re-
quires mentioning. The remaining 2 new trials on
alendronate25 and raloxifene26 were small studies (<60 par-
ticipants) that did not exclude patients with evidence of CKD-
MBD. These studies did not show consistent beneﬁcial effects
on DXA BMD. Generally, a major limitation is the lack of
data on fracture prevention by such therapeutic interventions
in advanced CKD (especially in CKD G5–G5D).
In summary, the aforementioned 4 prospective studies
evaluating BMD testing in adults with CKD represent a
substantial advance since the original guideline from 2009.
Despite the fact that they were conducted across a spectrum
of CKD severity, the ﬁnding that hip BMD predicted fractures
was consistent across studies, and 2 studies demonstrated
associations comparable to those seen in the absence of
CKD.11,13 Based on these insights, if a low or declining BMD
will lead to additional interventions to reduce falls or use
osteoporosis medications, then BMD assessment is
reasonable.Kidney International Supplements (2017) 7, 1–59Research recommendations
 RCTs are needed to determine whether interventions based
on DXA BMD are associated with lower fracture rates, and
whether the effects vary based on clinical variables such as
the baseline PTH level, underlying cause of kidney disease,
and CKD GFR category.
 Prospective studies are needed to determine whether
alternative imaging techniques, such as quantitative CT,
improve fracture prediction in CKD.
 Prospective studies are needed in children and adolescents
to determine whether DXA predicts fractures in children
and to determine whether the ISCD recommendations to
measure whole-body and spine BMD in children are the
appropriate sites in the context of CKD.17 Hip and radius
BMD pediatric reference data are now available and predict
incident fractures in healthy children and adolescents.27,28
3.2.2: In patients with CKD G3a–G5D, it is reasonable to
perform a bone biopsy if knowledge of the type of
renal osteodystrophy will impact treatment decisions
(Not Graded).
Rationale
Renal osteodystrophy is deﬁned as abnormal bone histology
and is 1 component of the bone abnormalities of CKD-
MBD.29 Bone biopsy is the gold standard for the diagnosis
and classiﬁcation for renal osteodystrophy. As detailed in the
2009 KDIGO CKD-MBD Guideline,30 DXA BMD does not
distinguish among types of renal osteodystrophy, and the
diagnostic utility of biochemical markers is limited by poor
sensitivity and speciﬁcity. Differences in PTH assays (e.g.,
intact vs. whole PTH) and reference ranges have contributed
to differences across studies. Unfortunately, cross-sectional
studies have provided conﬂicting information on the use of
biomarkers to predict underlying bone histology. This is not
surprising given the short half-lives of most of the circulating
biomarkers, and the long (3–6 months) bone remodeling
(turnover) cycle.
KDIGO recently led an international consortium to
conduct a cross-sectional retrospective diagnostic study of
biomarkers (all run in a single laboratory) and bone biopsies
in 492 dialysis patients.31 The objective was to determine the
predictive value of PTH (determined by both intact PTH
[iPTH] and whole PTH assays), bone-speciﬁc alkaline phos-
phatase (bALP), and amino-terminal propeptide of type 1
procollagen (P1NP) as markers of bone turnover. Although
iPTH, whole PTH, and bALP levels were associated with bone
turnover, no biomarker singly or in combination was sufﬁ-
ciently robust to diagnose low, normal, and high bone turn-
over in an individual patient. The conclusion was in support
of the 2009 KDIGO Guideline to use trends in PTH rather
than absolute “target” values when making decisions as to
whether to start or stop treatments to lower PTH. Table 1
provides the sensitivity, speciﬁcity, and positive and negative
predictive value of PTH in helping clinicians determine
therapies, demonstrating the challenges clinicians face. Thus,23
Table 1 | Utility of KDOQI and KDIGO PTH thresholds for diagnostic decision making
KDOQI* KDIGOD
Sens Spec PPV NPV Sens Spec PPV NPV
Differentiating low-turnover from non–low-turnover bone disease,
or “When do I stop therapy?”
69% 61% 72% 58% 66% 65% 73% 57%
Differentiating high-turnover from non–high-turnover bone disease,
or “When do I start therapy?”
58% 78% 35% 90% 37% 86% 35% 87%
iPTH, intact parathyroid hormone; KDIGO, Kidney Disease: Improving Global Outcomes; KDOQI, Kidney Disease Outcomes Quality Initiative; NPV, negative predictive value;
PPV, positive predictive value; PTH, parathyroid hormone; Sens, sensitivity; Spec, speciﬁcity.
*Using serum iPTH < 150 pg/ml (16 pmol/l) for lower and > 300 pg/ml (32 pmol/l) for upper threshold.
þUsing serum iPTH < 130 pg/ml (14 pmol/l) for lower and > 585 pg/ml (62 pmol/l) for upper threshold (2X and 9X of upper limit of normal for assay).
Reproduced with permission from Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated
by dialysis. Am J Kidney Dis. 2016;67:559–566.
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PTH to guide therapy, and when trends in PTH are incon-
sistent, a bone biopsy should be considered.
A bone biopsy should also be considered in patients with
unexplained fractures, refractory hypercalcemia, suspicion of
osteomalacia, an atypical response to standard therapies for
elevated PTH, or progressive decreases in BMD despite
standard therapy. The goal of a bone biopsy would be to: (i)
rule out atypical or unexpected bone pathology; (ii) deter-
mine whether the patient has high- or low-turnover disease,
which may alter the dose of medications to treat renal
osteodystrophy (e.g., initiate or discontinue calcimimetics,
calcitriol, or vitamin D analogs); or (iii) identify a minerali-
zation defect that would alter treatment (e.g., stop intake of
aluminum, or aggressively treat hypophosphatemia or
vitamin D deﬁciency).
The 2009 Guideline recommended a bone biopsy prior to
antiresorptive therapy in patients with CKD G4 to G5D and
evidence of biochemical abnormalities of CKD-MBD, low
BMD, and/or fragility fractures. The rationale was that low
BMD may be due to CKD-MBD (e.g., high PTH) and that
lowering PTH is a safer and more appropriate therapy than an
antiresorptive. In addition, there was concern that
bisphosphonates would induce low-turnover bone disease.
This was based on a single cross-sectional study in 13 patients
with CKD G2 to G4 that were referred for bone biopsy after a
variable duration of bisphosphonate therapy.32 To date,
studies in patients with CKD have not deﬁnitively demon-
strated that bisphosphonates cause adynamic bone disease.
Furthermore, the concerns in patients with CKD are only
theoretical, as it is well established that antiresorptive medi-
cations suppress bone formation rates, even in the absence of
kidney disease. For example, in an RCTof zoledronic acid for
the treatment of postmenopausal osteoporosis, bALP levels
were 59% lower in the zoledronic acid group compared with
the placebo group at 12 months.33
Despite these limitations, in weighing the risk-beneﬁt ratio
of bisphosphonate treatment, the 2009 KDIGO Guideline
suggested a biopsy prior to therapy. Since 2009, an additional24antiresorptive treatment (denosumab) has proven to be
effective in CKD G3a to G3b and G4, as discussed in
Recommendation 3.2.1. The growing experience with osteo-
porosis medications in patients with CKD increases the
comfort of treating patients with low BMD and a high risk of
fracture with antiresorptive therapy, although deﬁnitive trials
are lacking. Furthermore, additional data clearly support that
the incidence of fracture is markedly increased in patients
with CKD, and thus the inability to perform a bone biopsy
may not justify withholding antiresorptive therapy to patients
at high risk of fracture. Thus, the Work Group voted to
remove the requirement of bone biopsy prior to the use of
antiresorptive therapy for osteoporosis because the use of
these drugs must be individualized in patients with CKD.
However, it is still prudent that these drugs be used with
caution and that the underlying renal osteodystrophy be
addressed ﬁrst. With regard to efﬁcacy, one may speculate that
antiresorptive therapies confer less beneﬁt in the absence of
activated osteoclasts, as is the case in adynamic bone disease.
Moreover, additional side effects such as acute kidney injury
may also merit consideration in CKD G3a to G5.
In summary, bone biopsy is the gold standard for the
assessment of renal osteodystrophy and should be considered
in patients in whom the etiology of clinical symptoms and
biochemical abnormalities is in question, and the results may
lead to changes in therapy. With this statement, the Work
Group is well aware that experience concerning performance
and evaluation of bone biopsies is limited in many centers.34
With this in mind, in addition to the growing evidence that
antiresorptive therapies are effective in patients with CKD
G3a to G3b and G4, and the lack of robust evidence that these
medications induce adynamic bone disease, the guideline no
longer suggests that a bone biopsy be performed prior to
initiation of these medications.
Research recommendation
 Prospective studies of circulating biomarkers are needed to
determine whether they can predict changes in bone
histology.Kidney International Supplements (2017) 7, 1–59
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lowering high serum phosphate and maintaining
serum calcium4.1.1: In patients with CKD G3a–G5D, treatments of CKD-
MBD should be based on serial assessments of
phosphate, calcium, and PTH levels, considered
together (Not Graded).Rationale
The previous Recommendation 4.1.1 from the 2009 KDIGO
CKD-MBD guideline gave treatment directions concerning
serum phosphate levels in different GFR categories of CKD.
The accumulated evidence on this issue to date is now
depicted in Supplementary Tables S49–S51, S53–S55. Results
of this evidence review can be summarized as follows: most
studies showed increasing risk of all-cause mortality with
increasing levels of serum phosphate in a consistent and
direct fashion, with moderate risk of bias and low quality of
evidence, thus not essentially different from the study results
before 2009. For GFR decline and cardiovascular event rate,
results were considered less conclusive.
Serum phosphate, calcium, and PTH concentrations are all
routinely measured in CKD patients, and clinical decisions
are often made based on these values. However, the results of
these tests are inﬂuenced by food intake, adherence to and the
timing of drug intake and dietary modiﬁcations, differences
in assay methods and their intra-assay coefﬁcient of variation
(CV), and also by the interval from the last dialysis session in
CKD G5D patients. Furthermore, it has recently been sug-
gested that these markers undergo signiﬁcant diurnal changes
even in CKD patients.35,36 Accordingly, the decision should be
based not on a single result, but rather on the trends of serial
results, which stands very much in accordance to 2009
Recommendation 3.1.4. In addition, recent post hoc analyses
of large dialysis cohorts suggest that the prognostic implica-
tions of individual biochemical components of CKD-MBD
largely depend on their context with regard to constellations
of the full array of MBD biomarkers.37 This analysis identiﬁed
a wide range of CKD-MBD phenotypes, based on phosphate,
calcium, and PTH measurements categorized into mutually
exclusive categories of low, medium, and high levels using
previous Kidney Disease Outcomes Quality Initiative
(KDOQI)/KDIGO guideline targets, further illustrating
important potential interactions between components of
CKD-MBD in terms of risk prediction for death or cardio-
vascular events. This analysis, however, did not provide
guidance for treatment, because it is unknown whetherKidney International Supplements (2017) 7, 1–59switching from “risk classes” parallels changes in incidence of
complications or mortality over time. Of note, biomarkers
such as bALP and 25(OH)vitamin D were also still considered
valuable, but as no new evidence has been published on their
account, recommendations remained unchanged from the
previous guideline (2009 Recommendations 3.1.3, 3.2.3).
Finally, therapeutic maneuvers aimed at improving 1
parameter often have unintentional effects on other parame-
ters, as exempliﬁed by the recent EVOLVE trial.38 The guideline
Work Group considered it reasonable to take the context of
therapeutic interventions into account when assessing values of
phosphate, calcium, and PTH, and felt that it was important to
emphasize the interdependency of these biochemical param-
eters for clinical therapeutic decision making.
Based on these assumptions, it was also decided to split
previous 2009 Recommendation 4.1.1 into 2 new Recom-
mendations, 4.1.1 (diagnostic recommendation based on
accumulated observational evidence) and 4.1.2 (therapeutic
recommendation based mostly on RCTs).
Research recommendations
 Prospective cohort studies or RCTs are needed to evaluate
whether changes inCKD-MBDriskmarker patterns over time
associate with changes in risk (e.g., multiple interventions).
 Prospective cohort studies or RCTs are needed to examine
whether biochemical abnormalities of CKD-MBD must be
weighed differently when induced by pharmacotherapy
compared with baseline values (e.g., past experience with
hemoglobin as risk predictor vs. active treatment to targets
by erythropoiesis-stimulating agents).
 Investigations contributing to the understanding of the
usefulness of ﬁbroblast growth factor 23 (FGF23) as a
complementary marker for treatment indications (e.g.,
phosphate-lowering therapies to halt CKD progression)
and direct treatment target (e.g., regression of left ventric-
ular hypertrophy [LVH]) should be undertaken.
4.1.2: In patients with CKD G3a–G5D, we suggest lowering
elevated phosphate levels toward the normal range
(2C).
Rationale
As outlined above, since publication of the 2009 KDIGO
CKD-MBD Guideline, additional high-quality evidence now
links higher concentrations of phosphate with mortality25
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plantation39–48 (Supplementary Tables S49–S51, S53–S55),
although some studies did not conﬁrm this association.49,50
However, trial data demonstrating that treatments that lower
serum phosphate will improve patient-centered outcomes are
still lacking, and therefore the strength of this recommendation
remains weak (2C). The rationale of interventions, therefore, is
still only based on epidemiological evidence as described above
and biological plausibility pointing to possible phosphorus
toxicity as recently summarized.51 Three recent historical
cohort analyses from DOPPS, ArMORR, and COSMOS were
not eligible for this evidence-based review; however, it is
noteworthy that these analyses suggested that those dialysis
patients who had been prescribed phosphate-binder therapy
showed improved survival.52–54 It is important to note that
phosphate-binder prescription was associated with better
nutritional status. Indeed, correction formarkers of nutritional
status in the DOPPS study did mitigate the strength of the
association, yet a statistically signiﬁcant beneﬁt persisted. In
addition, propensity scoring attempting to correct for selection
bias and subgroup analysis applied by Isakova et al.53 in the
ArMORR cohort suggested robustness of the beneﬁcial ﬁnd-
ings for those treated with phosphate binders. However, re-
sidual confounding still cannot be completely ruled out, and
due to the nature of the observational data, these studies did
not affect the current recommendation.
Methods to prevent the development of hyper-
phosphatemia essentially include dietary modiﬁcation, the
use of phosphate-lowering therapy, and intensiﬁed dialysis
schedules for those with CKD G5D. In the 2009 KDIGO
Guideline it was suggested to maintain serum phosphate in
the normal range in the predialysis setting and lower serum
phosphate toward the normal range in patients on dialysis.
Interestingly, in the prospective observational COSMOS
study cohort of HD patients (Supplementary Tables S49–S51,
S53–S55), the best patient survival was observed with serum
phosphate close to 4.4 mg/dl (1.42 mmol/l).55
The previous recommendation suggested that clinicians
“maintain serum phosphate in the normal range” for patients
with CKD G3a to G3b and G4. The Work Group reevaluated
the evidence underlying this assumption. The majority of
studies (Supplementary Table S49) found phosphate to be
consistently associated with excess mortality at levels above
and below the limits of normal, but not in the normal
range.40–43,47,48,56,57 This ﬁnding is in line with the previously
found U-shaped relation of phosphate with mortality risk in
dialysis patients.58 However, a recent trial comparing placebo
with active phosphate-binder therapy in predialysis patients
(CKDG3b–G4) with amean baseline phosphate concentration
of 4.2 mg/dl (1.36 mmol/l), found a minimal decline in serum
phosphate, no effect on FGF23, and increases in coronary
calciﬁcation scores for the active treatment group59—calling
into question the efﬁcacy and safety of phosphate binding in
this population, with normal phosphate concentration prior to
initiation of binder treatment (Supplementary Tables S19–24).
In this analysis, all phosphate binders were analyzed26collectively, and the study was underpowered to detect differ-
ences between phosphate binders. Although the data suggested
that the observed increase in coronary artery calciﬁcation
(CAC) was mainly driven by the group treated with calcium-
containing phosphate binders, those treated with calcium-
free binders had no advantage over placebo in terms of pro-
gression of CAC. In addition, a well-executed mineral balance
study in predialysis patients using calcium-containing phos-
phate binders demonstrated the absence of any effect on
phosphate balance (while showing in the short term a positive
calcium balance).60
The second principal option to control phosphate in pre-
dialysis patients is dietary restriction, as will be addressed in
Recommendation 4.1.8. However, in both the NHANES and
MDRD cohorts that examined the general population and
advanced CKD, respectively, dietary intake or intervention to
reduce dietary phosphate intake as assessed by either urinary
excretion or dietary recall had only minimal effects on serum
phosphate.61,62 It is unknown whether this minimal decline in
serum phosphate concentrations or the more robust lower
phosphate intake translates into beneﬁcial clinical outcome. A
subsequent analysis of the MDRD study found no impact of
low phosphate intake as compared with higher intake on car-
diovascular disease or all-causemortality.63 It needs to be noted
that in this study baseline phosphate levels were normal on
average, so results are possibly not applicable to CKD patients
with progressively or persistently elevated serum phosphate
(see rationale for Recommendation 4.1.5).
Taken together, the key insights from these data were: (i)
the association between serum phosphate and clinical
outcome is not monotonic; (ii) there is a lack of demon-
strated efﬁcacy of phosphate binders for lowering serum
phosphate in patients with CKD G3a to G4; (iii) the safety of
phosphate binders in this population is unproven; and (iv)
there is an absence of data showing that dietary phosphate
restriction improves clinical outcomes. Consequently, the
Work Group has abandoned the previous suggestion to
maintain phosphate in the normal range, instead suggesting
that treatment be focused on patients with hyper-
phosphatemia. The Work Group recognizes that preventing,
rather than treating, hyperphosphatemia may be of value in
patients with CKD G3a to G5D, but acknowledges that current
data are inadequate to support the safety or efﬁcacy of such an
approach and encourages research in this speciﬁc area.
Only 2 RCTs have examined phosphate-lowering therapy in
children with CKD or on dialysis;64,65 due to the low number
of patients and short follow-up, both studies did not meet
literature inclusion criteria set a priori together with the
evidence review team (ERT). The ﬁrst RCT examined
biochemical endpoints only and showed equivalent phosphate
control with calcium acetate and sevelamer hydrochloride in
an 8-week cross-over trial.65 In the second, 29 children were
randomized to different combinations of phosphate binders
and vitamin D analogs; bone biopsies suggested that the
sevelamer group had reduced bone formation versus baseline
at 8-month follow-up, but numbers were too small forKidney International Supplements (2017) 7, 1–59
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Several studies in children on dialysis have shown an associ-
ation between high phosphate levels and increased vessel
thickness,66–68 vessel stiffness68,69 and CAC.67,68,70,71 In young
adults on dialysis, the CAC score was shown to double within
20 months, and progression was associated with higher serum
phosphate levels.71
Research recommendations
 RCTs for controlling hyperphosphatemia in patients with
CKD G3a to G5D, with appropriate follow-up and power,
should be conducted to assess various phosphate-lowering
therapy strategies for reducing the incidence of patient-
level endpoints (e.g., CKD progression) in children and
adults.
 RCTs of low and high dietary phosphate intake in patients
in CKD G3a to G5 should be conducted to test the hy-
pothesis that high dietary phosphate intake increases car-
diovascular risk either directly or indirectly through
induction of FGF23.
 If the feasibility of a placebo-controlled trial is threatened
due to perceived lack of equipoise (i.e., “unethical” to not
lower elevated serum phosphate levels, despite the lack of
high-quality data), a prospective trial comparing 2 different
phosphate targets in patients with CKD G3a to G5D is
encouraged.
 RCTs should be conducted in normophosphatemic CKD
patients in order to test the hypothesis that active
compensatory mechanisms to counterbalance increased
phosphate intake (such as increases in FGF23 and PTH) are
associated with poorer clinical outcome, despite compara-
ble serum phosphate concentration. Interventions could
include dietary phosphate restriction, phosphate-binder
therapy, novel compounds to limit phosphate uptake, or a
combination thereof.
4.1.3: In adult patients with CKD G3a–G5D, we suggest
avoiding hypercalcemia (2C). In children with CKD
G3a–G5D, we suggest maintaining serum calcium in
the age-appropriate normal range (2C).
Rationale
As is the case for phosphate, novel epidemiological evidence
linking higher calcium concentrations to increased
mortality in adults with CKD has accumulated since the
2009 KDIGO CKD-MBD guideline (Supplementary
Tables S49–S50, S52–S55).42–44,47,50,60,72–74 Moreover, and in
addition to previous observations,48 novel studies link higher
concentrations of serum calcium to nonfatal cardiovascular
events.75,76 This consistency justiﬁes the change of this
recommendation from 2D to 2C, although the overall evi-
dence base remains limited due to the lack of prospective
controlled trial data.
Hypocalcemia is a classical feature of untreated CKD, in
part secondary to diminished gastrointestinal (GI) uptake of
calcium due to vitamin D deﬁciency.77 HypocalcemiaKidney International Supplements (2017) 7, 1–59contributes to the pathogenesis of secondary hyperparathy-
roidism (SHPT) and renal osteodystrophy. Therefore, the
previous recommendation suggested maintaining serum cal-
cium in the normal range, including the correction of hy-
pocalcemia. A more recent retrospective observational
analysis of a large dialysis cohort conﬁrmed the association
between hypocalcemia and mortality risk.50 Two other recent
observations, however, raised doubt within the KDIGO
guideline Work Group about the generalizability of the sug-
gestion to correct hypocalcemia. The ﬁrst is the potential
harm for some adults associated with a positive calcium
balance (while serum calcium levels do not necessarily reﬂect
calcium balance).78,79 The second observation is that the
prevalence of hypocalcemia may have increased after the
introduction of calcimimetics (cinacalcet) in patients on
dialysis.38,80,81 The clinical implications of this increased
incidence of low calcium due to the therapeutic institution of
a calcimimetic is uncertain, but may be less harmful. With
regard to the intention-to-treat (ITT) population of the
EVOLVE trial, no negative signals were associated with the
persistently low serum calcium levels in the cinacalcet arm of
the trial. Retaining the 2009 KDIGO Guideline on this issue
would support the concept that patients developing hypo-
calcemia during calcimimetic treatment require aggressive
calcium treatment. Given the unproven beneﬁts of this
treatment and the potential for harm, the Work Group
emphasizes an individualized approach to the treatment of
hypocalcemia rather than recommending the correction of
hypocalcemia for all patients. However, signiﬁcant or symp-
tomatic hypocalcemia should still be addressed. Symptomatic
or severe hypocalcemia may beneﬁt from correction to
prevent adverse consequences such as bone disease, hyper-
parathyroidism, and QTc interval prolongation.
Childhood and adolescence are critical periods for bone
mass accrual: in healthy children the calcium content of the
skeleton increases fromw25 g at birth tow1000 g in adults,
and w25% of total skeletal mass is laid down during the 2-
year interval of peak height velocity.82 The mean calcium
accretion rate in healthy pubertal boys and girls peaks at 359
and 284 mg/d, respectively.83 The updated evidence review
identiﬁed a prospective cohort study in 170 children
and adolescents with CKD G2 to G5D (Supplementary
Table S49–S50, S52–S55) that showed that lower serum cal-
cium levels were independently associated with lower cortical
volumetric BMD Z-scores.19 Over 1 year of follow-up in 89
children, a change in the cortical BMD Z-score positively
correlated with baseline calcium (P ¼ 0.008) and increase in
calcium (P ¼ 0.002) levels, particularly in growing children.
During the 1-year follow-up, 6.5% of children sustained a
fracture. Notably, a lower cortical BMD Z-score predicted
future fractures: the HR for fracture was 1.75 (95% CI: 1.15–
2.67; P ¼ 0.009) per SD decrease in baseline BMD.19
Thus, the Work Group recognizes the higher calcium re-
quirements of the growing skeleton and suggests that serum
calcium levels are maintained in the age-appropriate normal
range in children and adolescents.27
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 Calcium balance study in dialysis patients should be pur-
sued at baseline versus after start of calcimimetic treatment
(with and without calcium supplementation, adaptations in
dialysate calcium concentrations, and/or concomitant active
vitamin D analog treatment).
 RCTs in children and adolescents with CKD should be
conducted to determine whether calcium-based phosphate
binders, as compared with calcium-free phosphate binders,
promote bone accrual (as measured by bone density and
structure, and fractures), and to determine the impact of
phosphate binders on arterial calciﬁcation in the context of
the high calcium requirement of growing bones.
4.1.4: In patients with CKD G5D, we suggest using a dial-
ysate calcium concentration between 1.25 and 1.50
mmol/l (2.5 and 3.0 mEq/l) (2C).
Rationale
Based on the available evidence, the 2009 Work Group
considered that a dialysate calcium concentration of 1.25
mmol/l (2.5 mEq/l) would yield neutral calcium balance, but
this statement was subsequently challenged by kinetic
modeling studies.84
Two relevant new RCTs are available concerning this topic
(Supplementary Tables S13–S18).85,86 In the study by Spa-
sovski et al.,86 the effects of 2 different dialysate calcium
concentrations were examined in patients with adynamic
bone disease, and the lower dialysate calcium (1.25 mmol/l
[2.5 mEq/l]) was found to improve bone and mineral pa-
rameters compared with the higher concentration of 1.75
mmol/l (3.5 mEq/l). Their data conﬁrmed the results of
previous papers and also support individualization of dialy-
sate calcium concentrations as recommended previously by
the Work Group. The comparator in this study, however, was
a high dialysate calcium concentration of 1.75 mmol/l
(3.5 mEq/l), leaving open the possibility that lower levels
of dialysate calcium (>1.25 mmol/l [2.5 mEq/l] but
<1.75 mmol/l [3.5 mEq/l]) would be equally beneﬁcial.
Ok et al. randomized 425 HD patients with iPTH levels
< 300 pg/ml (32 pmol/l) and baseline dialysate calcium
concentrations between 1.5 and 1.75 mmol/l (3.0–3.5 mEq/l)
to concentrations of either 1.25 mmol/l (2.5 mEq/l) or
1.75 mmol/l (3.5 mEq/l).85 Lowering dialysate calcium levels
slowed the progression of CAC and improved biopsy-proven
bone turnover (low bone turnover decreased from 85.0% to
41.8%) in this cohort of patients on HD. In this trial, the
comparative effects of a 1.5 mmol/l (3.0 mEq/l) calcium
concentration were not addressed.
Retrospective observational data by Brunelli et al.87 sug-
gested safety concerns (i.e., heart failure events, hypotension)
associated with the default use of dialysate calcium
concentrations < 1.25 mmol/l (2.5 mEq/l). Conversely, at the
high end of dialysate calcium concentration (1.75 mmol/l
[3.5 mEq/l]), Kim et al.88 found increased risk for all-cause
mortality and cardiovascular or infection-related28hospitalization in incident HD patients for high dialysate cal-
cium. However, observational studies, in general, may not be
sufﬁcient to warrant changes to treatment recommendations.
Patients with mild hypocalcemia might potentially even
have a positive calcium mass transfer when dialyzed against a
concentration of 1.25 mmol/l (2.5 mEq/l), but no such
metabolic balance studies exist. Taken together, the Work
Group felt that this recommendation remains valid as written
in 2009 and that there is no new evidence justifying a change
in the wording. However, additional studies of better quality
are now available, and as such the evidence grade has been
upgraded from 2D to 2C.
Research recommendation
 Calcium balance studies should be performed with non–
calcium-containing versus calcium-containing phosphate
binders, and vitamin D sterols versus cinacalcet in different
calcium dialysate settings. These studies should include
children and adolescents and assess calcium balance in the
context of skeletal calcium accrual.
4.1.5: In patients with CKD G3a–G5D, decisions about
phosphate-lowering treatment should be based on
progressively or persistently elevated serum phos-
phate (Not Graded).
Rationale
With regard to 2017 Recommendation 4.1.5 (formerly 2009
Recommendation 4.1.4), the previous 2009 KDIGO CKD-
MBD guideline commented that available phosphate
binders are all effective in the treatment of hyper-
phosphatemia, and that there is evidence that calcium-free
binders may favor halting progression of vascular calciﬁca-
tions compared with calcium-containing binders.30 Concerns
about calcium balance and uncertainties about phosphate
lowering in CKD patients not on dialysis, coupled with
additional hard endpoint RCTs and a systematic review
(comparing effects on mortality for calcium-free vs. calcium-
containing phosphate binders), resulted in the decision to
reevaluate this recommendation.
Based on new pathophysiological insights into phosphate
regulation and the roles of FGF23 and (soluble) Klotho in
early CKD, clinical studies had been initiated investigating
phosphate-lowering therapies in CKD patients in whom
hyperphosphatemia had not yet developed. Here, the
concept of early phosphate retention, possibly represented
by increases in FGF23 serum or plasma concentrations, was
the focus of scientiﬁc attention. The most notable RCT
was performed by Block et al.59 In this study, predialysis
patients (CKD G3b–G4) with mean baseline serum phos-
phate concentrations of 4.2 mg/dl (1.36 mmol/l) were
exposed to 3 different phosphate binders (sevelamer,
lanthanum, or calcium acetate) versus matching placebos, in
order to explore effects on serum phosphate levels, urinary
phosphate excretion, serum FGF23 levels, vascular calciﬁca-
tion, bone density, etc., with a 9-month follow-upKidney International Supplements (2017) 7, 1–59
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decrease in serum phosphate concentrations (for those allo-
cated to active treatment) and a 22% decrease in urinary
phosphate excretion (suggesting adherence to therapy), no
differences in changes in FGF23 levels were observed versus
placebo, as already discussed in Recommendation 4.1.2. In
contrast to the authors’ expectations, progression of coronary
and aortic calciﬁcation was observed with active phosphate-
binder treatment, while there was no progression in the
placebo arm. Subgroup analysis suggested that this negative
effect was accounted for by calcium acetate treatment, but
neither calcium-free binders were superior to placebo with
regard to this surrogate endpoint.
This study was further supported by another metabolic
study in a small group of patients with CKD G3b to G4, in
whom the addition of 3  500 mg calcium carbonate to meals
containing 1 g of calcium and 1.5 g of phosphorus per day did
not affect baseline neutral phosphate balance, but caused a
signiﬁcantly positive calcium balance,60 at least in the short
term.Due to its low number of patients and short duration, this
study did not fulﬁll the predeﬁned inclusion criteria for full
evidence review. Nevertheless, in the Work Group’s opinion,
this well-performed metabolic study may present a plausible
and relevant safety signal, and thus should be mentioned here.
Both Block et al.59 and Hill et al.60 studied subjects with
essentially normal phosphate concentrations at baseline.
Thus, there may be 2 key messages from these studies. First,
normophosphatemia may not be an indication to start
phosphate-lowering treatments. Second, the concept that not
all phosphate binders are interchangeable must be noted.
Whether disproportional elevations in FGF23 serum con-
centrations may become a signal in order to start phosphate-
lowering therapies in early CKD will need to be investigated
in appropriate trial settings.
Considering these insights, especially regarding CKD pa-
tients not on dialysis, and as already suggested in the rationale
of Recommendation 4.1.2, the Work Group felt that the
updated guideline should clarify that phosphate-lowering
therapies may only be indicated in the event of “progressive
or persistent hyperphosphatemia,” and not to prevent
hyperphosphatemia. When thinking about risk-beneﬁt ratios,
even calcium-free binders may possess a potential for harm
(e.g., due to side effects such as GI distress and binding of
essential nutrients). The broader term “phosphate-lowering
therapies” instead of phosphate-binding agents was intro-
duced, because all possible approaches (i.e., binders, diet, and
dialysis) can be effective and because phosphate transport
inhibitors may expand the therapeutic armamentarium in the
not-so-distant future.
There have been no additional data since 2008 with regard
to “safe” phosphate level thresholds or hard endpoints (i.e.,
mortality, cardiovascular events, and progression of CKD)
from RCTs treating patients toward different phosphate (or
FGF23) targets. The previous qualiﬁers (presence of other
components of CKD-MBD, concomitant therapies, side effect
proﬁle) were deleted because the Work Group thought thatKidney International Supplements (2017) 7, 1–59their consideration was self-evident. Diurnal variation of
serum phosphate concentrations was discussed as another
pathophysiologically relevant aspect of evaluation.While it was
felt that these variations in daily phosphate levels do affect the
accuracy of evaluations, the notion of variable timing for blood
sampling was considered unfeasible in clinical routine practice
and therefore not included in the guideline text.
Research recommendations
 Prospective clinical trials studying the value of levels of
FGF23 (and possibly soluble Klotho) as indicators for
establishing phosphate-lowering therapies should be un-
dertaken; desirable endpoints should include: CKD pro-
gression, cardiovascular calciﬁcation, cardiovascular events,
and mortality.
 See research recommendations following Recommendation
4.1.2.
4.1.6: In adult patients with CKD G3a–G5D receiving
phosphate-lowering treatment, we suggest restrict-
ing the dose of calcium-based phosphate binders
(2B). In children with CKD G3a–G5D, it is reason-
able to base the choice of phosphate-lowering
treatment on serum calcium levels (Not Graded).
Rationale
The Work Group thought that the new available data and the
changes applied to 2009 Recommendation 4.1.4 (now
Recommendation 4.1.5) suggested a need to revise the 2009
Recommendation 4.1.5 (now Recommendation 4.1.6). The
balance study by Hill et al.60 supported results reported by
Spiegel and Brady79 in normophosphatemic adults with CKD
G3b to G4, which suggested potential harms of liberal cal-
cium exposure in such cohorts, but due to their study designs
were not eligible for full evidence review by the ERT. The RCT
by Block et al.59 in a much larger, similar cohort and 2
additional RCTs in hyperphosphatemic CKD patients have
added hard endpoint data when prospectively comparing the
calcium-free binders, mostly sevelamer, with calcium-
containing binders in predialysis or dialysis adult patients,
respectively (Supplementary Tables S19–S24)59,89,90 These
results were also supported by results from recent systematic
reviews;91–94 however, because the evidence review team
(ERT) had considered all included studies separately and
individually during this update process, these meta-analyses
did not have additional bearing on the decision making by
the Work Group.
Overall, the Work Group determined that there is new
evidence suggesting that excess exposure to calcium through
diet, medications, or dialysate may be harmful across all GFR
categories of CKD, regardless of whether other candidate
markers of risk such as hypercalcemia, arterial calciﬁcation,
adynamic bone disease, or low PTH levels are also present.
Therefore, these previous qualiﬁers in the 2009 KDIGO
recommendation were deleted, acknowledging that they may
still be valid in high-risk scenarios.29
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patients showing signiﬁcant survival beneﬁts over a 3-year
interval for patients treated with sevelamer versus calcium-
containing binders (Supplementary Tables S19–S24).89,90
Both studies were analyzed by the ERT and were
graded as relevant RCTs with a moderate risk of bias
(Supplementary Tables S23 and S24), leading to a 2B
recommendation. Overall, the ﬁndings from all identiﬁed
studies seemed to show either a potential for beneﬁt or an
absence of harm associated with calcium-free phosphate-
binding agents to treat hyperphosphatemia compared with
calcium-based agents (Supplementary Tables S20 and S21).
The wording in Recommendation 4.1.6 of “restricting the
dose of calcium-based phosphate binders” was retained from
previous 2009 Recommendation 4.1.5; however, the qualiﬁer
that the recommendation applies to patients with persistent
or recurrent hypercalcemia was removed. Given the fact of 2
reasonably large RCTs demonstrating mortality risks associ-
ated with calcium-containing binder treatment, it was debated
within the Work Group whether the recommendation should
be stronger, possibly using “avoid” instead of “restrict.” How-
ever, some members of the Work Group felt that available
evidence does not conclusively demonstrate that calcium-free
agents are superior to calcium-based agents. In addition,
none of the studies provided sufﬁcient dose threshold infor-
mation about calcium exposure, nor did they give information
on the safety of moderately dosed calcium-containing binders
in combination therapies. Finally, because KDIGO guidelines
are intended for a global audience and calcium-free agents are
not available or affordable in all jurisdictions, recommending
against the use of calcium-based binders would imply that no
treatment is preferable to using calcium-based agents. Despite
the understandable clinical desire to have numeric targets and
limits, the Work Group could not make an explicit recom-
mendation about a maximum dose of calcium-based binders,
preferring to leave this to the judgment of individual physicians
while acknowledging the potential existence of a safe upper
limit of calcium dose. Of note, 2 short-term studies in stable
CKD patients not on dialysis found that positive calcium
balance may occur with total intakes as low as 800 and
1000 mg/d, respectively.60,79 Such short-terms results are
informative but not conclusive, and decisions must be indi-
vidualized for each patient.
The recent availability of iron-containing phosphate binders
was discussed within the Work Group but did not affect the
recommendations given the absence of data on long-term pa-
tient-centered outcomes in the published phase 3 trials.95–97
All of the above studies were limited to adults. Importantly,
concerns regarding the adverse effects of excess exposure to
calcium through diet, medications, or dialysate may not be
generalizable to children. Skeletal growth and development are
characterized by rapid calcium accrual,83 as described in
Recommendation 4.1.3. Furthermore, recent studies demon-
strated that bone accrual continues into the third decade of
life in healthy individuals, well beyond cessation of linear
growth.98,99 Of relevance to adolescentswithCKD, bone accrual30between ages 18 and 24was especially pronounced among those
with late puberty.100 Therefore, studies of calcium- and non–
calcium-containing binders and other therapies that impact
calcium balance should consider the needs of the developing
skeleton. The observation that serum calcium levels were
positively associated with increases in BMD in children with
CKD, and that this association was signiﬁcantly more pro-
nounced with greater linear growth velocity,19 illustrates the
unique needs of the growing skeleton (see Recommendation
4.1.3). Lastly, a recent prospective cohort study in 537 children
with predialysis CKD demonstrated that phosphate-binder
treatment (calcium-based in 82%) was associated with
decreased risk of incident fractures (HR: 0.37, 95% CI: 0.15–
0.91), independent of age, sex, eGFR, and PTH levels.101
Although this study did not meet the criteria for inclusion in
the evidence review, it highlights the need for additional studies
in children. There is a lack of data suggesting adverse effects of
excess exposure to calcium through diet, medications or dial-
ysate in children. The Work Group concluded that there was
insufﬁcient evidence to change this recommendation in chil-
dren, who may be uniquely vulnerable to calcium restriction.
Research recommendations
 Calcium and phosphate balance studies should be con-
ducted using different calcium-based binder doses and
combinations with calcium-free binders in hyper-
phosphatemic patients across all GFR categories of CKD.
 RCTs assessing the effect of iron-based phosphate binders on
patient-centered and surrogate outcomes across all GFR cat-
egories of CKD should be undertaken; comparators should be
placebo, calcium-based binders, orother calcium-free binders.
 RCTs using phosphate transport inhibitors (e.g., nicotin-
amide,102 tenapanor103) as “add-on” treatments in patients
with resistant hyperphosphatemia should be investigated.
 Prospective clinical and balance studies should examine the
role of magnesium as a phosphate binder, with regard to
patient-centered outcomes, calciﬁcation, and cardiovascular
event rates.
 RCTs in children and adolescents with CKD should be
conducted to determine whether calcium-based phosphate
binders, as compared with calcium-free phosphate binders,
promote bone accrual (as measured by bone density and
structure, and fractures), and to determine the impact of
phosphate binders on arterial calciﬁcation in the context of
the high calcium requirement of growing bones.
4.1.8: In patients with CKD G3a–G5D, we suggest limiting
dietary phosphate intake in the treatment of hyper-
phosphatemia alone or in combination with other
treatments (2D). It is reasonable to consider phos-
phate source (e.g., animal, vegetable, additives) in
making dietary recommendations (Not Graded).
Rationale
There was no general controversy toward the 2009 KDIGO
CKD-MBD Guideline on dietary phosphate restriction as anKidney International Supplements (2017) 7, 1–59
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levels, but previous 2009 recommendation 4.1.7 (now 4.1.8)
on limiting dietary phosphate intake was considered vague,
especially with regard to new evidence on different phosphate
and phosphoprotein sources. Within this guideline update,
predeﬁned criteria on study duration and cohort size pro-
hibited inclusion of some study reports for full evidence
review. Nevertheless, the Work Group felt that some of these
reports presented safety signals demanding a brief discussion.
As summarized in Supplementary Tables S25–S30, only 2
studies on this topic in dialysis patients fulﬁlled the evidence
review criteria.104,105 Both studies investigated the impact of
intensiﬁed versus routine dietary counseling on serum
phosphate levels after a follow-up of 6 months. In both
studies, the intensiﬁed counseling groups more successfully
reached the laboratory targets; however, no hard endpoints
were documented. Accordingly, the quality of evidence
for outcome was rated as very low. Similarly, a recent
Cochrane review concluded that there is low-quality evidence
that dietary interventions positively affect CKD-MBD
biomarkers.106
The daily phosphate intake for a typical American diet
varies with age and gender. A majority of young to middle-
aged men take in more than 1600 mg/d, whereas women in
the same age groups take in about 1000 mg/d.107 On a
global scale, there are quite signiﬁcant differences in diet
compositions to be considered. Estimates of dietary phos-
phate from food composition tables likely underestimate the
phosphate content because they may mostly reﬂect the
“natural” phosphate content of foods that are highest (e.g.,
dairy products, meats, poultry, ﬁsh, and grains). There are
actually 3 major sources of phosphates: natural phosphates
(as cellular and protein constituents) contained in raw or
unprocessed foods, phosphates added to foods during pro-
cessing, and phosphates in dietary supplements/medications.
Russo et al.108 assessed the effect of dietary phosphate
restriction on the progression of CAC. This study was not
designed to compare the efﬁcacy of phosphate binders against
dietary phosphate restriction. However, they found that di-
etary phosphate restriction alone did not lead to a decrease in
urinary phosphate excretion, nor did it prevent progression of
CAC. However, the urine data cast doubt on compliance with
the diet, and there was no control group on a normal or high-
phosphate diet.
Aggressive dietary phosphate restriction is difﬁcult because
it has the potential to compromise adequate intake of other
nutrients, especially protein. Zeller et al.109 showed that the
restriction of dietary protein and phosphate could be achieved
with maintenance of good nutrition status with intense
counseling. They demonstrated that dietary protein/phos-
phate restriction resulted in a signiﬁcant reduction in urinary
phosphate excretion when compared with a control diet.
Dietary supplements and over-the-counter or prescription
medications are hidden sources of phosphate. They may
contain phosphate salts within their inactive ingredients. The
data on the amount of phosphate in oral medications andKidney International Supplements (2017) 7, 1–59vitamin/mineral supplements is limited, but they have the
potential to contribute signiﬁcantly to the phosphate load
considering the number of medications CKD patients are
required to take.110,111
Another consideration for modiﬁcation of dietary phos-
phate and control of serum phosphate is the “bioavailability”
of phosphorus in different foods based on the form—organic
versus inorganic sources of phosphate. Animal- and plant-
based foods contain the organic form of phosphate. Food
additives contain inorganic phosphate. About 40% to 60% of
animal-based phosphate is absorbed, depending on the GI
vitamin D receptor activations. Plant phosphate, mostly
associated with phytates, is less absorbable (generally 20%–
50%) in the human GI tract. It behooves the dietitian and
other interdisciplinary staff to include education about the
best food choices as they relate to absorbable phosphate.
Additionally, it is important for patients to be guided toward
fresh and homemade foods rather than processed foods in
order to avoid additives.
Organic phosphate in such plant foods as seeds and
legumes is less bioavailable because of limited GI absorption
of phytate-based phosphorus. In this context, Moe et al.35
recently demonstrated that a vegetable-based diet showed
signiﬁcantly lower phosphate absorption versus a meat-based
diet with similar phosphate content. Inorganic phosphate is
more readily absorbed, and its presence in additive-laden
processed, preserved, or enhanced foods or soft drinks is
likely to be underreported in nutrient databases. Hence, the
phosphate burden from food additives is disproportionately
high relative to natural sources that are derived from organic
(animal and vegetable) food proteins, and these additives are
almost completely absorbed in the GI tract. For example,
Benini et al. showed that foods that contain phosphate
additives have a phosphorus content nearly 70% higher than
those that do not contain additives.112 Sherman and Mehta
also demonstrated that phosphate contents between unpro-
cessed and processed meat or poultry may differ by more than
60%, and thus the absorbable phosphate may even be 2 to 3
times higher per weight in processed food.113
In contrast, many of the foods that are traditionally labeled
as high phosphorus may be more acceptable with the
knowledge that the phosphorus is absorbed more slowly and
not as efﬁciently. For example, beans and nuts have always
been listed as very high in phosphorus; however, considering
their lower absorption rate, they may be acceptable as protein
sources, if they are not too high in other nutrients such as
potassium.
The amount of phosphorus contributed by food intake is
increasing with current and new processing practices that
utilize phosphorus-containing ingredients, including popular
foods such as restructured meats (formed, pressed, rolled, and
shaped for ease of preparation and ingestion), processed and
spreadable cheeses, “instant” products (puddings, sauces),
frozen breaded products, and soft drinks.114 Phosphate ad-
ditives are also widely used in fast foods and convenience
foods that are fully or partially pre-made or instant.11031
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results for control of serum phosphate. Intense education
focusing on phosphate intake has been useful to reduce
retention in some studies.105,115 A simple education tool on
how to read food labels and “look for PHOS” (the study
acronym) was successful in helping dialysis patients reduce
their phosphate intake. A magnifying glass was provided to
help patients read labels,116 as well as instructions available to
guide “better choices” in fast-food restaurants. Other studies
have had less favorable results.117
Taken together, these insights led the Work Group to the
decision to not change the principal recommendation, but to
add a qualiﬁer statement suggesting that phosphate sources
should be better substantiated and patient education should
focus on best choices. Finally, it must be emphasized that
efforts to restrict dietary phosphate must not compromise
adequate protein intake.32Research recommendations
 RCTs comparing low,medium, and high phosphate intake on
phosphate metabolism and homeostasis, including responses
concerning FGF23, PTH, calciﬁcation, and CKDprogression,
in patients in CKD G3b to G4, should be performed.
 In such study designs, the role of the phosphate quality
should be studied: vegetable versus meat versus additive
sources.
 Kinetic and balance studies on the uptake of phosphate
additives in dialysis patients should be performed.
 Prospective trials identifying the most effective phosphate-
lowering approach (beneﬁt-risk-cost ratio) should be per-
formed across all CKD GFR categories—such as how best
to combine phosphate binders, phosphate transport in-
hibitors and diet (plus dialysis treatment in CKD G5D)—
with appropriate patient-centered and surrogate endpoints
in mind (e.g., calciﬁcation, FGF23 levels, and LVH).Kidney International Supplements (2017) 7, 1–59
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CKD-MBD4.2.1: In patients with CKD G3a–G5 not on dialysis, the
optimal PTH level is not known. However, we suggest
that patients with levels of intact PTH progressively
rising or persistently above the upper normal limit
for the assay be evaluated for modiﬁable factors,
including hyperphosphatemia, hypocalcemia, high
phosphate intake, and vitamin D deﬁciency (2C).
Rationale
The pathogenesis of SHPT is complex and driven by several
factors, including vitamin D deﬁciency, hypocalcemia, and
hyperphosphatemia. Elevated FGF23 concentrations exacer-
bate SHPT through further reductions in 1,25(OH)2 vitamin
D (calcitriol) levels. Calcitriol deﬁciency results in decreased
intestinal absorption of calcium and may lead to hypocalce-
mia, a major stimulus for PTH secretion. This leads to
parathyroid cell proliferation, contributing to SHPT. The
incidence and severity of SHPT increases as kidney function
declines and can lead to signiﬁcant abnormalities in bone
mineralization and turnover.
The 2009 KDIGO CKD-MBD Guideline recommended
addressing modiﬁable risk factors for all patients with a PTH
level above the upper limit of normal for the assay used.30
Unfortunately, there is still an absence of RCTs that deﬁne
an optimal PTH level for patients with CKD G3a to G5, or
clinical endpoints of hospitalization, fracture, or mortality.
The Work Group felt that modest increases in PTH may
represent an appropriate adaptive response to declining kid-
ney function, due to its phosphaturic effects and increasing
bone resistance to PTH,118 and have revised this statement to
include “persistently” above the upper normal PTH level as
well as “progressively rising” PTH levels, rather than simply
“above the upper normal limit” as in the 2009 KDIGO
Guideline. Thus, treatment should not be based on a single
elevated value.
Although the optimal PTH is not known, the Work Group
felt that rising PTH levels in CKD G3a-G5 warrant exami-
nation of modiﬁable factors, such as vitamin D insufﬁciency
or deﬁciency, hypocalcemia, and hyperphosphatemia. In the
interval since the 2009 KDIGO Guideline, 1 eligible RCT
examined the impact of cholecalciferol supplementation
(Supplementary Table S31) and 3 examined the impact of
phosphate binders on PTH levels in the nondialysis
CKD population. Oksa et al.119 reported an RCT of a
high (20,000 international units [IU]/wk) versus low
(5,000 IU/wk) dose of cholecalciferol supplementation in 87Kidney International Supplements (2017) 7, 1–59adults with CKD G2 to G4 (Supplementary Tables S31–S36).
Serum 25(OH) vitamin D levels increased signiﬁcantly in
both groups and were signiﬁcantly greater in the high-dose
arm at the completion of the 12-month intervention. PTH
levels decreased signiﬁcantly in both groups; however, the
PTH levels did not differ signiﬁcantly between groups at the
completion of the study. In this context, Recommendation
3.1.3 on native vitamin D supplementation remains valid
from the previous 2009 guideline publication.
Three recent RCTs in the nondialysis CKD population
evaluated phosphate binders and their effects on surrogate
endpoints, such as vascular calciﬁcation, arterial compliance,
left ventricular mass, and BMD, as well as calcium, phosphate,
and PTH levels. Two RCTs compared sevelamer with placebo
(Supplementary Tables S31–S36), the ﬁrst in 109 nondiabetic
CKD G3a to G3b patients120 and the second in 117 CKD
patients with a mean eGFR of 36  17 ml/min/1.73 m2.121
The studies were conducted over 36 weeks and 24 months,
respectively, and neither study demonstrated signiﬁcant dif-
ferences in PTH levels between sevelamer and placebo groups.
Another RCT involving 148 CKD patients (eGFR: 20–45 ml/
min/1.73 m2) compared placebo with 3 different phosphate
binders (calcium-based, lanthanum, and sevelamer) over a
9-month period and reported that PTH levels remained stable
in those on active therapy (combined phosphate-binder
groups) but increased by 21% in the placebo group
(P ¼ 0.002)59 (Supplementary Table S33).
In the updated recommendation, an additional modiﬁable
risk factor, “high phosphate intake,” was added because of the
increasing recognition that excess phosphate intake does not
always result in hyperphosphatemia, especially in early CKD,
and that high phosphate intake may promote SHPT. While
dietary phosphate, whether from food or additives, is modi-
ﬁable, better methods for assessment of dietary phosphate
intake are required.
4.2.2: In adult patients with CKD G3a–G5 not on dialysis,
we suggest that calcitriol and vitamin D analogs not
be routinely used (2C). It is reasonable to reserve the
use of calcitriol and vitamin D analogs for patients
with CKD G4–G5 with severe and progressive
hyperparathyroidism (Not Graded).
In children, calcitriol and vitamin D analogs may be
considered to maintain serum calcium levels in the
age-appropriate normal range (Not Graded).33
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Prevention and treatment of SHPT is important because
imbalances in mineral metabolism are associated with CKD-
MBD and higher PTH levels are associated with increased
morbidity and mortality in CKD patients. Calcitriol and other
vitamin D analogs have been the mainstay of treatment of
SHPT in individuals with CKD for many decades. The 2009
KDIGO CKD-MBD Guideline summarized multiple studies
demonstrating that administration of calcitriol or vitamin D
analogs (such as paricalcitol, doxercalciferol, and alfacalcidol)
resulted in suppression of PTH levels.30 However, there was a
notable lack of trials demonstrating improvements in patient-
centered outcomes.
Multiple well-conducted RCTs cited in the 2009 guideline
reported beneﬁts of calcitriol or vitamin D analogs in treating
SHPT in patients with CKD G3a to G5; 2 primarily involved
biochemical endpoints,122,123 and 2 evaluated bone histo-
morphometry.124,125 Despite the lack of hard clinical end-
points, these data led to the original recommendation to treat
elevated PTH with calcitriol or vitamin D analogs early in
CKD to prevent parathyroid hyperplasia and its skeletal
consequences (2C). Although beneﬁts were predominantly
related to suppression of SHPT, adverse effects of hypercal-
cemia were noted to be of concern in the 2009 KDIGO CKD-
MBD Guideline.30
The effects of vitamin D therapy on biochemical endpoints
in CKD have been previously documented, especially with
regard to reduced PTH levels. Numerous previous studies
have reported signiﬁcant reductions of PTH levels with cal-
citriol or vitamin D analogs in CKD G3a to G3b and G4 when
compared with placebo123,125,126 and recent RCTs have also
demonstrated that vitamin D treatment effectively lowers
PTH levels in CKD G3a to G5.127,128
Additional RCTs of calcitriol or vitamin D analog therapy
have been published since the 2009 KDIGO CKD-MBD
Guideline (Supplementary Tables S37–S42). Two, in partic-
ular, demonstrated a signiﬁcantly increased risk of hypercal-
cemia in patients treated with paricalcitol, compared with
placebo, in the absence of beneﬁcial effects on surrogate
cardiac endpoints, as detailed below.127,128 These results,
combined with the opinion that moderate PTH elevations
may represent an appropriate adaptive response, led the Work
Group to conclude that the risk-beneﬁt ratio of treating
moderate PTH elevations was no longer favorable and that
the use of calcitriol or vitamin D analogs should be reserved
for only severe and progressive SHPT.
The 2 recent RCTs were designed to detect potential beneﬁts
of calcitriol or vitamin D analogs on cardiac structure and
function, as measured by magnetic resonance imaging (MRI),
in adults with CKD (Supplementary Tables S37–S42). The
rationale for these studies is that calcitriol and vitamin D an-
alogs act through the vitamin D receptor (VDR) to exert their
beneﬁts to inhibit PTH secretion, and the VDR is also present
in many tissues and organs including vascular smooth muscle,
endothelial cells, and the heart. The key evidence for changes in
Recommendation 4.2.2 predominantly came from these trials.34The ﬁrst study was a double-blind RCT by Thadhani et al.
(the PRIMO study), where participants with CKD G3a to G4,
mild to moderate LVH, and PTH levels between 50 and 300
pg/ml (5.3–32 pmol/l) were assigned to placebo (n ¼ 112) or
paricalcitol (n ¼ 115) to test the primary hypothesis that
paricalcitol will reduce left ventricular mass index (LVMI)
over a 48-week interval.128 Paricalcitol was administered at a
dose of 2 mg/d, with protocol-speciﬁed dose reduction to
1 mg/d, if the serum calcium was > 11 mg/dl (2.75 mmol/l).
Baseline PTH levels were approximately 1.5 times the upper
limit of normal. The ITT analysis revealed that paricalcitol did
not reduce LVMI, nor did it modify diastolic function. Of
subjects on paricalcitol, the mean serum calcium increased by
0.32 mg/dl (0.08 mmol/l) (95% CI: 0.19–0.45 mg/dl; 0.05–
0.11 mmol/l) versus a decrease by 0.25 mg/dl (0.06 mmol/l)
(95% CI: 0.37 to 0.12 mg/dl; 0.09 to –0.03 mmol/l) in
the placebo group. Hypercalcemia was deﬁned as 2 consec-
utive measurements of serum calcium > 10.5 mg/dl (> 2.63
mmol/l), and the number of patients requiring dose
reductions from 2 mg/d to 1 mg/d and episodes of
hypercalcemia were more common in the paricalcitol group
(22.6%) compared with the placebo (0.9%) group.
In the second key study, a double-blind RCT by Wang et al.
(the OPERA study), subjects with CKD G3a to G5, LVH, and
PTH $ 55 pg/ml (5.83 pmol/l) were randomly assigned to
receive paricalcitol (n ¼ 30) or placebo (n ¼ 30).127 The
primary endpoint was change in LVMI over 52 weeks. Base-
line PTH levels were approximately twice the upper limit of
normal. Change in LVMI did not differ signiﬁcantly between
groups, nor did secondary outcomes such as measures of
systolic and diastolic function. The median (interquartile
range) changes in serum calcium were 0.08 mmol/l (0.32 mg/
dl) (95% CI: 0.02–0.16 mmol/l; 0.08–0.64 mg/dl) and 0.01
mmol/l (0.04 mg/dl) (95% CI: –0.06 to 0.05 mmol/l; –0.24 to
0.2 mg/dl) in the paricalcitol and placebo arms, respectively.
Hypercalcemia, deﬁned as any serum calcium > 2.55 mmol/l
(> 10.2 mg/dl), occurred in 43.3% and 3.3% of participants
in the paricalcitol and placebo arms, respectively. Of note,
70% of those who were hypercalcemic received concomitant
calcium-based phosphate binders. Generally the hypercalce-
mia was mild and could be corrected by stopping the binder
without changing the paricalcitol dose.
Recent meta-analyses were largely conﬁrmatory and sup-
ported the hypercalcemia risk association with calcitriol and
vitamin D analogs.129,130
The evidence review identiﬁed 2 RCTs comparing par-
icalcitol with calcitriol (Supplementary Tables S37–S42);
neither demonstrated differences in the incidence of hypercal-
cemia.131,132 Coyne et al.131 compared calcitriol (0.25 mg/d)
with paricalcitol (1 mg/d) in 110 patients with CKDG3a to G3b
and G4 and PTH > 120 pg/ml (12.7 pmol/l). The change in
PTH was comparable in the 2 arms (a decline of 52% vs. 46%)
over the 6-month trial, and the incidence of hypercalcemia was
very low in both groups (only 3 with paricalcitol and 1 with
calcitriol). Further details regarding changes in biochemical
parameters are provided in Supplementary Tables S37–S42.Kidney International Supplements (2017) 7, 1–59
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vitamin D supplementation (cholecalciferol and ergo-
calciferol), which can also suppress PTH (especially in CKD
G3a–G3b) and decrease hypercalcemia because the normal
homeostatic loops that suppress the CYP27B remain intact.
However, no studies of sufﬁcient duration were identiﬁed in
this evidence review, and thus this therapy remains unproven.
Several studies have assessed the effect of PTH-lowering
comparing nutritional vitamin D supplements and calcitriol
or vitamin D analogs.133,134 However, these studies were not
identiﬁed in this evidence review because of their short
duration.
The use of extended-release calcifediol, a novel vitamin D
prohormone, to correct low serum 25(OH) vitamin D levels
and lower PTH has also been recently studied. This agent
reduces the catabolism of both 25(OH) vitamin D and
1,25(OH)2 vitamin D and increases levels of both. An RCTof
429 patients with CKD G3a to G3b and G4 published after our
guideline systematic review reported at least a 10% reduction of
intact PTH levels in 72% of participants after 12 months, with
no signiﬁcant impact on calcium, phosphate, or FGF23
levels.135 No patient-level outcomes were reported, and thus
this study did not impact the current recommendation.
All of the above studies were conducted in adults. A recent
Cochrane review examined vitamin D therapy for bone dis-
ease in children with CKD G2 to G5 on dialysis.136 Bone
disease, as assessed by changes in PTH levels, was improved
by all vitamin D preparations regardless of route or
frequency of administration. The prospective cohort study
demonstrated that high PTH levels were independently
associated with reduced cortical BMD Z-scores at baseline
(P ¼ 0.002) and 1-year follow-up (P < 0.001).19 High PTH
levels are associated with CAC in children on dialysis.67,68 The
Cochrane review has not shown any signiﬁcant difference in
hypercalcemia risk with vitamin D preparations compared
with placebo, but 1 study showed a signiﬁcantly greater risk of
hypercalcemia with i.v. calcitriol administration.136 No dif-
ference in growth rates was detected between different
vitamin D analogs or use of oral or i.v. vitamin D treat-
ments.136 As noted in Recommendation 4.1.3, the Work
Group recommended that serum calcium should be main-
tained within age-appropriate reference range in children, and
given the association of high PTH levels with reduced bone
mineralization and increased vascular calciﬁcation, children
are likely to require calcitriol or other active vitamin D analog
therapy.
In summary, the PRIMO and OPERA studies failed to
demonstrate improvements in clinically relevant outcomes
but demonstrated increased risk of hypercalcemia. Accord-
ingly, the guideline no longer recommends routine use of
calcitriol or its analogs in CKD G3a to G5. This was not a
uniform consensus among the Work Group. It should be
noted that the participants in the PRIMO and OPERA trials
only had moderately increased PTH levels, thus therapy with
calcitriol and vitamin D analogs may be considered in those
with progressive and severe SHPT.Kidney International Supplements (2017) 7, 1–59There are still no RCTs demonstrating beneﬁcial effects of
calcitriol or vitamin D analogs on patient-level outcomes,
such as cardiac events or mortality, and the optimal level of
PTH in CKD G3a to G5 is not known. Furthermore, therapy
with these agents may have additional harmful effects related
to increases in serum phosphate and FGF23 levels. If initiated
for severe and progressive SHPT, calcitriol or vitamin D an-
alogs should be started with low doses, independent of the
initial PTH concentration, and then titrated based on the
PTH response. Hypercalcemia should be avoided.
Research recommendation
 Multicenter RCTs should be conducted in children and
adults to determine the beneﬁts or harms of calcitriol or
vitamin D analogs in patients with CKD G3a to G5;
patient-level outcomes including falls, fractures, sarcopenia,
muscle strength, physical function, progression to end-stage
kidney disease, cardiovascular events, hospitalizations, and
mortality should be assessed. Additional important patient-
level outcomes to include are bone pain, pruritus, and
health-related quality of life. Studies should also include
patients with more severe SHPT and should determine the
impact of reducing PTH to different target levels, such as
the normal range versus higher levels.
4.2.4: In patients with CKD G5D requiring PTH-lowering
therapy, we suggest calcimimetics, calcitriol, or
vitamin D analogs, or a combination of calcimimetics
with calcitriol or vitamin D analogs (2B).
Rationale
New data published since the 2013 KDIGO Madrid Contro-
versies Conference prompted the Work Group to reappraise
the use of PTH-lowering therapies in patients with CKD G5D.
As shown in Supplementary Table S43, the ERT identiﬁed 2
new trials evaluating treatment with cinacalcet versus placebo
and 1 new trial evaluating calcitriol versus a vitamin D analog.
One open-label clinical trial was conducted evaluating the
effect of cinacalcet on bone histomorphometry.145 There are
still no new trials of calcitriol or vitamin D analogs that
demonstrated clear beneﬁts in patient-level outcomes.
The Work Group discussed the EVOLVE trial at length.
EVOLVE evaluated the effect of cinacalcet versus placebo on
patient-level outcomes in 3883 HD patients using a composite
endpoint of all-cause mortality, nonfatal myocardial infarc-
tion, hospitalization for unstable angina, congestive heart
failure, and peripheral vascular events. Secondary endpoints
included individual components of the primary endpoint,
clinical fracture, stroke, parathyroidectomy, and cardiovas-
cular events and cardiovascular death.38
The results of EVOLVE have proven controversial. The
unadjusted primary composite endpoint showed a nonsig-
niﬁcant reduction (HR: 0.93; P ¼ 0.112) with cinacalcet use.
However, analyses adjusted for imbalances in baseline char-
acteristics demonstrated a nominally signiﬁcant reduction in
the primary composite endpoint (HR: 0.88; P ¼ 0.008), as did35
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randomized study medication (HR: 0.77; 95% CI: 0.70–
0.92)137 or when patients were censored at the time of kidney
transplant, parathyroidectomy, or the use of commercial
cinacalcet (HR: 0.84; P # 0.001).38 Further challenging the
interpretation of the nonsigniﬁcant reduction in risk seen
with the unadjusted primary endpoint was a signiﬁcant
treatment-age interaction (P ¼ 0.03),38 leading to speculation
that cinacalcet may be effective predominantly in older dial-
ysis patients. Approximately one-third of the EVOLVE par-
ticipants were under the age of 55, and prespeciﬁed analyses
that evaluated subjects above or below age 65 demonstrated a
signiﬁcant reduction in risk associated with use of cinacalcet
for both the primary endpoint (HR: 0.74; P # 0.001) and all-
cause mortality (HR: 0.73; P # 0.001) for those aged
above 65.138
The Work Group also considered additional prespeciﬁed
and post hoc analyses from EVOLVE. These included a
demonstrated signiﬁcant reduction in the risk of severe un-
remitting SHPT (deﬁned by the persistence of markedly
elevated PTH concentrations [2 consecutive PTH values over
1000 pg/ml (106 pmol/l)] together with hypercalcemia
[serum calcium > 10.5 mg/dl (2.63 mmol/l)] or para-
thyroidectomy). Cinacalcet appeared to consistently reduce
the risk of this endpoint regardless of baseline PTH (HR: 0.31,
P# 0.001 for those with baseline PTH 300–600 pg/ml [32–64
pmol/l]; HR: 0.49, P # 0.001 for those with baseline PTH
600–900 pg/ml [64–95 pmol/l]; HR: 0.41, P < 0.001 for those
with PTH > 900 pg/ml [95 pmol/l]).139 Cinacalcet had no
effect on the risk of clinical fractures in unadjusted analyses
(HR: 0.93; P ¼ 0.111) and showed a nominally signiﬁcant
reduction in risk of fracture when adjusted for age (HR: 0.88;
P ¼ 0.007).140
Thus, EVOLVE did not meet its primary endpoint that
cinacalcet reduces the risk of death or clinically important
vascular events in CKD G5D patients. However, the results of
secondary analyses suggest that cinacalcet may be beneﬁcial in
this population or a subset. There was a lack of uniform
consensus among the Work Group members in their inter-
pretation of these data with regard to establishing cinacalcet as
the recommended ﬁrst-line therapy for patients with CKD
G5D requiring PTH-lowering therapy. While some felt that
only the primary analysis should be used to interpret the
outcome, others were equally convinced that the secondary
analyses strongly suggested a beneﬁt of treatment with cina-
calcet on important patient-level outcomes.
Despite these differences in interpretation, there was
agreement among Work Group members that the higher cost
of cinacalcet was also a relevant consideration given its un-
certain clinical beneﬁts. There was also agreement that the
documented association between good clinical outcomes and
the extent of FGF23 reduction with cinacalcet warrants
further study.141
No trials demonstrated the beneﬁts of combination ther-
apy (cinacalcet plus another agent) on clinically relevant
outcomes. However, several additional RCTs were identiﬁed36that studied the effect of combination therapy on putative
surrogate outcomes (summarized in Supplementary
Tables S43–S48). Two trials evaluated the use of cinacalcet
with low-dose active vitamin D versus standard therapy.
Urena-Torres et al.142 demonstrated improved PTH-lowering
efﬁcacy in subjects treated with cinacalcet or low-dose active
vitamin D, while Raggi et al.143 found that cinacalcet with
low-dose vitamin D attenuated the progression of coronary
artery calcium accumulation when assessed using calcium
volume scores (P ¼ 0.009) although not when using the more
common Agatston score (P ¼ 0.07). Two open-label trials of
cinacalcet were considered important in reaching consensus
for Recommendation 4.2.4. The PARADIGM trial compared a
cinacalcet-based treatment strategy with an active vitamin D–
based strategy in 312 HD patients and demonstrated similar
reductions in PTH in both treatment arms.144 The BONA-
FIDE trial evaluated bone histomorphometry in 77 paired
bone biopsy samples in cinacalcet-treated subjects with
proven high-turnover bone disease and demonstrated re-
ductions in bone formation rates and substantial increase in
the number of subjects with normal bone histology (from 0 at
baseline to 20 after 6–12 months of therapy).145 Two subjects
developed adynamic bone disease, both of whom had PTH
values < 150 pg/ml (16 pmol/l), and 1 patient developed
osteomalacia coincident with hypophosphatemia. Despite
being a prospective interventional trial, the BONAFIDE trial
did not fulﬁll our literature inclusion criteria, because there
was no control group and only longitudinal assessments were
available, and thus is not listed in the Supplementary Tables.
It was recognized by the Work Group that newer, i.v.
calcimimetic agents have undergone clinical trial investigation
and were published after our guideline systematic review.
However, while data on safety and efﬁcacy were generated, no
patient-level outcomes were reported. Therefore, these trials
did not impact the current recommendation.146,147
In summary, the Work Group was divided as to whether
the EVOLVE data are sufﬁcient to recommend cinacalcet as
ﬁrst-line therapy for all patients with SHPT and CKD G5D
requiring PTH lowering. One viewpoint is that the primary
endpoint of the EVOLVE study was negative. The alternative
viewpoint is that secondary analyses found effects on patient-
level endpoints, while there are no positive data on mortality
or patient-centered endpoints from trials with calcitriol or
other vitamin D analogs. Given the lack of uniform consensus
among the Work Group and the higher acquisition cost of
cinacalcet, it was decided to modify the 2009 recommenda-
tion to list all acceptable treatment options in alphabetical
order. The individual choice should continue to be guided by
considerations about concomitant therapies and the present
calcium and phosphate levels. In addition, the choice of
dialysate calcium concentrations will impact on serum PTH
levels. Finally, it should be pointed out that para-
thyroidectomy remains a valid treatment option especially in
cases when PTH-lowering therapies fail, as advocated in
Recommendation 4.2.5 from the 2009 KDIGO CKD-MBD
guideline.Kidney International Supplements (2017) 7, 1–59
www.kisupplements.org chap te r 4 . 2To date, studies of cinacalcet in children are limited to case
reports,148 case series,149,150 a single-center experience (with
28 patients with CKD G4–G5),151 and an open-label study of
a single dose in 12 children on dialysis.152 In recognition of
the unique calcium demands of the growing skeleton, PTH-
lowering therapies should be used with caution in children
to avoid hypocalcemia. Future studies are needed in children
before pediatric-speciﬁc recommendations can be issued.
Research recommendations
 The Work Group explicitly endorses the presence of clinical
equipoise and the need to conduct placebo-controlled trials
with calcimimetics versus standard therapy for theKidney International Supplements (2017) 7, 1–59treatment of SHPT in patients with CKD G5D with
emphasis on those at greatest risk (e.g., older, with
cardiovascular disease).
 Prospective RCTs aiming at patient-centered surrogate
outcomes (primary endpoints: mortality, cardiovascular
events; secondary endpoints: FGF23, LVH progression,
calciﬁcation) should be performed with the new parenteral
calcimimetic compound (e.g., etelcalcitide).
 Given the disparate effects of calcimimetic and active
vitamin D therapies on FGF23 and data suggesting a clinical
beneﬁt from FGF23 reduction, RCTs evaluating the speciﬁc
reduction of FGF23 as a therapeutic endpoint should be
undertaken.37
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bisphosphonates, other osteoporosis medications,
and growth hormone4.3.3: In patients with CKD G3a–G5D with biochemical
abnormalities of CKD-MBD and low BMD and/or
fragility fractures, we suggest that treatment choices
take into account the magnitude and reversibility of
the biochemical abnormalities and the progression
of CKD, with consideration of a bone biopsy (2D).
Rationale
Recommendation 3.2.2 now addresses the indications for a
bone biopsy prior to antiresorptive and other osteoporosis
therapies. Therefore, the original Recommendation 4.3.438from the 2009 KDIGO CKD-MBD Guideline has been
removed, and Recommendation 4.3.3 has broadened from
CKD G3a to G3b to CKD G3a to G5D. Nevertheless, when
such treatment choices are considered, their speciﬁc side ef-
fects must also be taken into account (e.g., antiresorptives will
exacerbate low bone turnover, denosumab may induce sig-
niﬁcant hypocalcemia), and the risk of their administration
must be weighed against the accuracy of the diagnosis of the
underlying bone phenotype.Kidney International Supplements (2017) 7, 1–59
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transplant bone disease5.5: In patients with CKD G1T–G5T with risk factors for
osteoporosis, we suggest that BMD testing be used to
assess fracture risk if results will alter therapy (2C).The
ﬁrsRationale
Fracture risk is 4-fold higher in patients with end-stage kid-
ney disease153 compared with the general population and
increases further in the early post-transplant period.154 A
2002 study examined the risk of hip fracture in kidney
transplant recipients and estimated the fracture rate at 3.3
events per 1000 person-years, a 34% higher risk compared
with patients receiving dialysis who were waitlisted for
transplantation.3 Bone disease in transplant recipients is
complex and heterogeneous.155 Essentially, transplant bone
disease is the composite of preexisting damage to the bone
acquired during the period of renal insufﬁciency and damage
to the bone starting in the period of transplantation. In
contrast to older studies,156 recent cohort studies showed
minimal BMD losses in the early post-transplant period,
which seem to be restricted to sites rich in cortical bone such
as the distal radius.157 A low cumulative steroid exposure
along with persistent hyperparathyroidism most likely ac-
counts for this shift.157 The widespread implementation of
steroid minimization protocols may explain the favorable
trend in fracture risk in kidney transplant recipients observed
over the last 2 decades.158–160
The 2009 KDIGO CKD-MBD Guideline30 recommended
BMD testing in the ﬁrst 3 months following transplantation
in patients with an eGFR greater than 30 ml/min/1.73 m2 if
they receive corticosteroids or have risk factors for osteopo-
rosis (Recommendation 5.5), but recommended that DXA
BMD not be performed in those with CKD G4T to G5T
(Recommendation 5.7). As detailed in the new aforemen-
tioned Recommendation 3.2.1, there is growing evidence that
DXA BMD predicts fractures across the spectrum of CKD
severity, including 4 prospective cohort studies in patients
with CKD G3a to G5D10–13 (Supplementary Tables S7–S12).
To date, there are no prospective studies addressing the ability
of DXA to predict fractures in transplant recipients. However,
a retrospective cohort study conducted in 238 kidney trans-
plant recipients with CKD G1T to G5T examined the asso-
ciations of DXA BMD with fracture events.161 Lumbar spine
and total-hip BMD results were expressed as T-scores and
categorized as normal (T-score $ 1), osteopenic (T-
score < 1 and > 2.5), or osteoporotic (T-score # 2.5).
A total of 46 incident fractures were recorded in 53 patients.Kidney International Supplements (2017) 7, 1–59In a multivariate Cox analysis of DXA BMD results in the
total hip, osteopenia (HR: 2.7, 95% CI: 1.6–4.6) and osteo-
porosis (HR: 3.5, 95% CI: 1.8–6.4) were associated with
signiﬁcantly increased risk of fracture compared with normal
BMD, independent of age, sex, and diabetes. Multivariate
models were not provided for the lumbar spine BMD T-score
results; however, unadjusted analyses suggested that spine
BMD provided less fracture prediction compared with total-
hip BMD. Although this DXA study in kidney transplant
recipients was not eligible for the evidence-based review due
to its retrospective design, the Work Group concluded that
the ﬁndings were consistent with the other studies in CKD
G3a to G5D described above.
In summary, there is growing evidence that DXA BMD
predicts fractures in patients with CKD across the spectrum,
with limited data suggesting these ﬁndings extend to trans-
plant recipients. The revised guideline statement recommends
BMD testing in transplant recipients, as in those with CKD
G3a to G5D, if the results will impact treatment decisions.
Research recommendations
 The research recommendations outlined for Recommen-
dation 3.2.1 should be expanded to include studies in
kidney transplant recipients.
 Prospective studies in patients with CKD G1T to G5T
should be performed to determine the value of BMD and
bone biomarkers as predictors of fractures.
5.6: In patients in the ﬁrst 12 months after kidney trans-
plant with an estimated glomerular ﬁltration rate
greater than approximately 30 ml/min/1.73 m2 and low
BMD, we suggest that treatment with vitamin D, cal-
citriol/alfacalcidol, and/or antiresorptive agents be
considered (2D).
 We suggest that treatment choices be inﬂuenced by
the presence of CKD-MBD, as indicated by abnormal
levels of calcium, phosphate, PTH, alkaline phos-
phatases, and 25(OH)D (2C).
 It is reasonable to consider a bone biopsy to guide
treatment (Not Graded).
re are insufﬁcient data to guide treatment after the
t 12 months.Rationale
The rationale for revised guideline Recommendation 3.2.2
now addresses the indications for a bone biopsy prior to
antiresorptive and other osteoporosis therapies. Therefore,39
chap te r 5 www.kisupplements.orgthe second bullet statement above concerning bone biopsies
has been modiﬁed.
Cinacalcet is not approved for the treatment of hyper-
parathyroidism in kidney transplant recipients; however, it is
clinically used, especially in patients with signiﬁcant hyper-
calcemia. While efﬁciently correcting hypercalcemia, cina-
calcet so far has failed to show a beneﬁcial impact on bone
mineralization in the transplant population.162 Denosumab
was recently shown to effectively increase BMD in de novo
kidney transplant recipients.163 However, baseline BMD on40average was not very low in this trial, and there was no
progressive BMD loss in the control group. Furthermore, an
increased rate of urinary tract infections was observed. In
terms of safety and efﬁcacy, an RCT comparing denosumab
and bisphosphonates in eligible patients at risk may be a
reasonable future study approach. As pointed out in the
rationale for Recommendation 5.5, however, the urgency for
correcting bone mineralization in transplant recipients may
diminish due to the wide application of steroid minimization
schemes.159Kidney International Supplements (2017) 7, 1–59
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CKD-MBD guideline updatePurpose
In 2009, KDIGO developed a clinical practice guideline on
the diagnosis, evaluation, prevention, and treatment of
CKD-MBD.30 Because of the limited evidence, many of the
recommendations were deliberately vague.
In October of 2013, KDIGO held a Controversies
Conference to determine whether there was sufﬁcient new
evidence to support updating any of the recommendations.
Based on the discussions at the conference, the participants
opted for a “selective update” of the guideline.1
The purpose of this chapter is to describe the methods
used to conduct the evidence review and to develop and
update the guideline recommendations.
Overview of the Process
The process of updating the guideline consisted of the
following steps:
 Convening of a Controversies Conference to determine
whether sufﬁcient new data exist to support a reassessment
of the guideline
 Appointing a Work Group and an ERT
 Reﬁning the research questions
 Developing the search strategy, inclusion/exclusion criteria,
and data extraction tables
 Drafting the evidence matrices and evidence proﬁles
 Revising the recommendations
 Grading the quality of the evidence
 Grading the strength of the recommendation
Controversies Conference
In October 2013, KDIGO held a Controversies Conference
entitled, “CKD-MBD: Back to the Future,” in Madrid, Spain.1
The purpose of the conference was to determine whether there
was sufﬁcient new evidence to support updating any of the rec-
ommendations from the 2009 KDIGO guideline on the diag-
nosis, evaluation, prevention, and treatment of CKD-MBD.
Seventy-four experts in adult, pediatric, and transplant
nephrology, endocrinology, cardiology, bone histomorphometry
pathology, and epidemiology attended the conference.
Four topic areas were considered: (i) vascular calciﬁcation;
(ii) bone quality; (iii) calcium and phosphate; and (iv)
vitamin D and PTH. Each participant was assigned to 1 of the
4 topics based on their area of expertise. Participants identi-
ﬁed new studies in their topic area and answered a set of
questions to determine which recommendations required
reevaluation.1
The result was a list of recommendations to be
addressed in a selected update (i.e., to use speciﬁc methodsKidney International Supplements (2017) 7, 1–59to update only those parts of the guideline in need of
update). There was a public review of the scope of work for
the guideline.
Appointment of guideline Work Group and evidence
review team
The KDIGO co-chairs appointed 2 chairs for the Guideline
Work Group, who then assembled the Work Group to be
responsible for the development of the guideline. The Work
Group comprised domain experts, including individuals with
expertise in adult and pediatric nephrology, bone disease,
cardiology, and nutrition. The Johns Hopkins University in
Baltimore, MD, was contracted as the ERT to provide
expertise in guideline development methodology and sys-
tematic evidence review. KDIGO support staff provided
administrative assistance and facilitated communication.
The ERT consisted of methodologists with expertise in
nephrology and internal medicine, and research associates
and assistants. The ERT and the Work Group worked closely
throughout the project. In January 2015, the ERT and the
Work Group Co-Chairs held a 2-day meeting in Baltimore,
MD, to discuss the guideline development and systematic
review processes and to reﬁne the key questions.
The ERT performed systematic reviews for each of the
questions conducting literature searches, abstract and full-text
screening, data extraction, risk of bias assessment, and syn-
thesis. The ERT provided suggestions and edits on the
wording of recommendations, and on the use of speciﬁc
grades for the strength of the recommendations and the
quality of evidence. The Work Group took on the primary
role of writing the recommendations and rationale, and
retained ﬁnal responsibility for the content of the recom-
mendations and the accompanying narrative.
Reﬁnement of the research questions
The ﬁrst task was to deﬁne the overall topics and goals for the
guideline. Using the recommendations identiﬁed during the
Controversies Conference, the ERT drafted research ques-
tions and identiﬁed the population, interventions, compari-
son, and outcomes (PICO elements) for each research
question.
The ERT recruited a technical expert panel to review the
research questions. The technical expert panel included in-
ternal and external clinicians and researchers in nephrology
and CKD. During a conference call, the technical expert panel
provided feedback on the research questions.
The Work Group Co-Chairs and the ERT reﬁned the
research questions at the 2-day meeting in Baltimore, MD.41
Table 2 | Research questions
Section
2009
rec. no. Research question Key outcomes Additional outcomes
Bone quality 3.2.1 In patients with CKD G3a–G5D, what is the
effect on bone quality of bisphosphonates,
teriparatide, denosumab, and raloxifene?
 TMV (as measured by bone
biopsy)
 BMD/bone mineral content
 Fracture
4.3.4 In patients with CKD G4–G5D, what is the
effect on bone quality of bisphosphonates,
teriparatide, denosumab, and raloxifene?
 TMV (as measured by bone
biopsy)
 BMD/bone mineral content
 Fracture
3.2.2 (a) In patients with CKD G3a–G5D, how well do
BMD results predict fractures?
(b) In patients with CKD G3a–G5D, how well do
BMD results predict renal osteodystrophy?
(a) Fracture
(b) TMV
5.5 In patients with CKD G1–G3b and transplant
recipients, how well do BMD results predict
fractures?
 Fracture
5.7 In patients with CKD G4–G5 and transplant
recipients, how well do BMD results predict
fractures?
 Fracture
Calcium and
phosphate
4.1.1 In patients with G3a–G5 or G5D, what is the
evidence for beneﬁt or harm in maintaining
serum phosphate in the normal range
compared with other targets of serum
phosphate in terms of biochemical outcomes,
other surrogate outcomes, and patient-
centered outcomes?
 Mortality
 GFR decline
 Cardiovascular and cerebrovas-
cular events
 Phosphate
 Bone histology, BMD
 Vascular and valvular calciﬁcation
imaging
 Hospitalizations
 Quality of life
 Kidney or kidney graft failure
 Fracture
 Parathyroidectomy
 Clinical adverse events
 Growth, skeletal deformities,
bone accrual
 Calciphylaxis/CUA
4.1.3 In patients with CKD G5D, what is the evidence
for beneﬁt or harm in using a dialysate calcium
concentration between 1.25 and 1.50 mmol/l
(2.5 and 3.0 mEq/l) compared with other
concentrations of dialysate calcium in terms of
biochemical outcomes, other surrogate
outcomes, and patient-centered outcomes?
 Mortality
 Cardiovascular and cerebrovas-
cular events
 Calcium
 Bone histology, BMD
 Vascular and valvular calciﬁcation
imaging
 Measures of GFR
 Hospitalizations
 Quality of life
 Kidney or kidney graft failure
 Fracture
 Parathyroidectomy
 Clinical adverse events
 Growth, skeletal deformities,
bone accrual
 Calciphylaxis/CUA
4.1.2 In patients with CKD G3a–G5D, what is the
evidence for beneﬁt or harm in maintaining
serum calcium in the normal range compared
with other targets of serum calcium in terms of
biochemical outcomes, other surrogate
outcomes, and patient-centered outcomes?
 Mortality
 Cardiovascular and cerebrovas-
cular events
 Calcium
 Bone histology, BMD
 Vascular and valvular calciﬁcation
imaging
 Measures of GFR
 Hospitalizations
 Quality of life
 Kidney or kidney graft failure
 Fracture
 Parathyroidectomy
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Section
2009
rec. no. Research question Key outcomes Additional outcomes
 Clinical adverse events
 Growth, skeletal deformities,
bone accrual
 Calciphylaxis/CUA
4.1.4 In patients with CKD G3a–G5 or G5D with
hyperphosphatemia, what is the evidence for
beneﬁt or harm in using calcium-containing
phosphate-binding agents to treat
hyperphosphatemia compared with calcium-
free phosphate-binding agents in terms of
biochemical outcomes, other surrogate
outcomes, and patient-centered outcomes?
 Mortality
 Cardiovascular and cerebrovas-
cular events
 Phosphate
 Bone histology, BMD
 Vascular and valvular calciﬁcation
imaging
 Measures of GFR
 Hospitalizations
 Quality of life
 Kidney or kidney graft failure
 Fracture
 Parathyroidectomy
 Clinical adverse events
 Growth, skeletal deformities,
bone accrual
 Calciphylaxis/CUA
4.1.7 In patients with CKD G3a–G5D with
hyperphosphatemia, what is the evidence for
beneﬁt or harm in limiting dietary phosphate
intake compared with a standard diet in terms
of biochemical outcomes, other surrogate
outcomes, and patient-centered outcomes?
 Mortality
 Cardiovascular and cerebrovas-
cular events
 Vascular and valvular calciﬁcation
 Phosphate
 Bone histology, BMD
 Measures of GFR
 Hospitalizations
 Quality of life
 Kidney or kidney graft failure
 Fracture
 Parathyroidectomy
 Clinical adverse events
 Growth, skeletal deformities,
bone accrual
 Calciphylaxis/CUA
Vitamin D
and PTH
4.2.1 In patients with CKD G3a–G5 not on dialysis
with levels of intact PTH above the upper
normal limit of the assay, what is the evidence
for beneﬁt or harm in reducing dietary
phosphate intake or treating with phosphate-
binding agents, calcium supplements, or
native vitamin D in terms of biochemical
outcomes, other surrogate outcomes, and
patient-centered outcomes?
 Mortality
 Cardiovascular and cerebrovas-
cular events
 GFR decline
 Calcium
 Phosphate
 Parathyroid hormone
 25-hydroxyvitamin D [25(OH)D]
 1,25-dihydroxyvitamin D
[1,25(OH)2D]
 Alkaline phosphatases
 Bone-speciﬁc alkaline
phosphatase
 Bicarbonate
 FGF23
 Bone histology, BMD
 Vascular and valvular calciﬁcation
imaging
 Measures of GFR
 Hospitalizations
 Quality of life
 Kidney or kidney graft failure
 Fracture
 Parathyroidectomy
 Clinical adverse events
 Growth, skeletal deformities,
bone accrual
 Calciphylaxis/CUA
4.2.2 In patients with CKD G3a–G5 not on dialysis, in
whom serum PTH is progressively rising and
remains persistently above the upper limit of
normal for the assay despite correction of
modiﬁable factors, what is the evidence for
 LVH
 Hypercalcemia
 Mortality
 Cardiovascular and cerebrovas-
cular events
 Calcium
 Phosphate
 Parathyroid hormone
 25-hydroxyvitamin D [25(OH)D]
(Continued on next page)
Table 2 | (Continued)
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Section
2009
rec. no. Research question Key outcomes Additional outcomes
beneﬁt or harm in treating with calcitriol or
vitamin D analogs compared with placebo or
active control in terms of biochemical
outcomes, other surrogate outcomes, and
patient-centered outcomes?
 1,25-dihydroxyvitamin D
[1,25(OH)2D]
 Alkaline phosphatases
 Bone-speciﬁc alkaline
phosphatase
 Bicarbonate
 FGF23
 Bone histology, BMD
 Vascular and valvular calciﬁcation
imaging
 Measures of GFR
 Hospitalizations
 Quality of life
 Kidney or kidney graft failure
 Fracture
 Parathyroidectomy
 Clinical adverse events
 Growth, skeletal deformities,
bone accrual
 Calciphylaxis/CUA
4.2.4 In patients with CKD G5D, what is the evidence
for beneﬁt or harm in treating with calcitriol,
vitamin D analogs, calcimimetics or
combination thereof compared with placebo
or active control in terms of biochemical
outcomes, other surrogate outcomes, and
patient-centered outcomes?
 Mortality
 Cardiovascular and cerebrovas-
cular events
 Fracture
 Vascular and valvular calciﬁcation
imaging
 Calcium
 Phosphate
 Parathyroid hormone
 25-hydroxyvitamin D [25(OH)D]
 1,25-dihydroxyvitamin D
[1,25(OH)2D]
 Alkaline phosphatases
 Bone-speciﬁc alkaline
phosphatase
 Bicarbonate
 FGF23
 Bone histology, BMD
 Vascular and valvular calciﬁcation
imaging
 Measures of GFR
 Hospitalizations
 Quality of life
 Kidney or kidney graft failure
 Fracture
 Parathyroidectomy
 Clinical adverse events
 Growth, skeletal deformities,
bone accrual
 Calciphylaxis/CUA
BMD, bone mineral density; CKD, chronic kidney disease; CUA, calciﬁc uremic arteriolopathy; GFR, glomerular ﬁltration rate; FGF23, ﬁbroblast growth factor 23; LVH, left
ventricular hypertrophy; PTH, parathyroid hormone; rec. no., recommendation number; TMV, bone turnover mineralization volume.
Table 2 | (Continued) Research questions
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comes, including those considered most important for deci-
sion making that would be graded (key outcomes). The
ﬁnalized research questions and outcomes are presented in
Table 2.
Search strategy
The ERT searched MEDLINE and the Cochrane Central
Register of Controlled Trials (CENTRAL) for the date range
of December 2006 through September 2015. The December
2006 date provided the recommended 1-year overlap with the
end of the previous search.164 The search yield was also
supplemented by articles provided by the Work Group
members through February 2017.44The search strategy included MeSH and text terms for
CKD and the interventions and markers of interest
(Supplementary Appendix A) and was limited to the English
language. The ERT also reviewed the list of references that
were suggested during the Controversies Conference.
All studies that had been included in the prior guideline
were rereviewed to ensure that they met the eligibility criteria.
Inclusion and exclusion criteria.With input from the Work
Group, the ERT deﬁned the eligibility criteria a priori. The
eligibility criteria for all studies were: (i) original data pub-
lished in English, (ii) followed up at least 10 patients with
CKD for at least 6 months, and (iii) addressed 1 of the
research questions. The minimum mean duration of follow-
up of 6 months was chosen on the basis of clinicalKidney International Supplements (2017) 7, 1–59
Table 3 | Question-speciﬁc eligibility criteria
2009 recommendation no. Exposure or intervention Eligibility criteria
3.2.1, 4.3.4 Bisphosphonates, teriparatide,
denosumab, or raloxifene
 RCT with at least 10 participants per arm for the outcome of bone quality and
at least 25 participants per arm for all other outcomes
 Evaluates bone quality, bone mineral density, or fracture
3.2.2, 5.5, 5.7 Predictive value of BMD results  RCT with at least 25 participants per arm or a prospective cohort study with
50 participants
 Evaluates fractures or renal osteodystrophy
4.1.1, 4.1.2 Serum phosphate or serum calcium
levels
 RCT with at least 25 participants per arm or a prospective cohort study with
50 participants
 Evaluates mortality, GFR decline, cardiovascular or cerebrovascular events,
phosphate levels, calcium levels, bone histology, bone mineral density, bone
volume, vascular and valvular calciﬁcation imaging, hospitalizations, quality
of life, kidney or kidney graft failure, fractures, parathyroidectomy, clinical
adverse events, growth, skeletal deformities, bone accrual, or calciphylaxis or
calciﬁc uremic arteriolopathy
4.1.3 Dialysate calcium concentrations  RCT with at least 25 participants per arm
 Evaluates mortality, cardiovascular or cerebrovascular events, calcium levels,
bone histology, bone mineral density, bone volume, vascular and valvular
calciﬁcation imaging, measures of GFR, hospitalizations, quality of life, kidney
or kidney graft failure, fractures, parathyroidectomy, clinical adverse events,
growth, skeletal deformities, bone accrual, or calciphylaxis or calciﬁc uremic
arteriolopathy
4.1.4, 4.1.7, 4.2.1, 4.2.2, 4.2.4 Dietary phosphate intake,
phosphate-binding agents, calcium
supplements, native vitamin D,
vitamin D analogs, calcitriol, or
calcimimetics
 RCT with at least 25 participants per arm
 Evaluates mortality, cardiovascular or cerebrovascular events, GFR decline,
calcium levels, phosphate levels, parathyroid hormone levels, 25-
hydroxyvitamin D or 1,25-dihydroxyvitamin D levels, alkaline phosphatases,
bone-speciﬁc alkaline phosphatase, bicarbonate, FGF23, bone histology, bone
mineral density, bone volume, vascular and valvular calciﬁcation imaging,
measures of GFR, hospitalizations, quality of life, kidney or kidney graft failure,
fractures, parathyroidectomy, clinical adverse events, growth, skeletal de-
formities, bone accrual, calciphylaxis or calciﬁc uremic arteriolopathy for any of
the above interventions, or LVH or hypercalcemia for vitamin D analogs
BMD, bone mineral density; FGF23, ﬁbroblast growth factor 23; GFR, glomerular ﬁltration rate; LVH, left ventricular hypertrophy; RCT, randomized controlled trial.
www.kisupplements.org me thodo log i ca l app roachreasoning, accounting for the hypothetical mechanisms of
action. For treatments of interest, the proposed effects on
patient-centered outcomes require long-term exposure and
typically would not be evident before several months of
follow-up. The question-speciﬁc eligibility criteria are pro-
vided in Table 3, and the overall search yield for the guideline
systematic review is summarized in Supplementary Appendix
B.
Two reviewers independently screened titles and abstracts
and full-text articles for inclusion. Differences regarding in-
clusion were resolved through consensus adjudication.
Any study not meeting the inclusion criteria could be cited
in the narrative but was not considered part of the body of
evidence for a particular recommendation.
Data extraction
TheERTmodiﬁed theonline supplementary tables from theprior
guideline.One reviewer abstracted data directly into themodiﬁed
tables, and a second reviewer conﬁrmed the data abstraction.
The ERT abstracted data on general study characteristics,
participant characteristics, interventions and co-interventions,
and outcome measures, including measures of variability.
Two reviewers independently assessed individual study
quality using the Cochrane Collaboration’s tool165 for
assessing risk of bias for RCTs and using the Quality in
Prognosis Studies tool166 for observational studies.Kidney International Supplements (2017) 7, 1–59The Work Group critically reviewed draft tables, and tables
were revised as appropriate.
Evidence matrices and evidence proﬁles
The ERT created evidence matrices for each of the key out-
comes for each research question. For each key outcome, the
matrix lists the individual studies, their sample size, follow-up
duration, and the individual study quality. The ERT also
drafted evidence proﬁles to display the total number and
overall quality of the studies addressing each key outcome for
each research question.
Revising recommendations
In June 2015, the Work Group and the ERT convened a 3-day
meeting in Baltimore, MD, to review the summary tables,
evidence proﬁles, and evidencematrices; to decide whether and
how the recommendations should be revised; and to determine
a grade that described the quality of the overall evidence and a
grade for the strength of each recommendation.
Grading
A structured approach—modeled after Grading of Recom-
mendations Assessment, Development, and Evaluation
(GRADE)167–172 and facilitated by the use of evidence proﬁles
and evidence matrices—was used to determine a grade that
described the quality of the overall evidence and a grade for
the strength of a recommendation. For each topic, the45
Table 4 | GRADE system for grading quality of evidence for an outcome
Step 1: starting grade for quality of
evidence based on study design Step 2: reduce grade Step 3: raise grade
Final grade for quality of
evidence for an outcomea
High for randomized controlled trials
Moderate for quasi-randomized trial
Low for observational study
Very low for any other evidence
Study quality
–1 level if serious limitations
–2 levels in very serious limitations
Consistency
–1 level if important inconsistency
Directness
–1 level if some uncertainty
–2 levels if major uncertainty
Other
–1 level if sparse or imprecise data
–1 level if high probability of
reporting bias
Strength of association
þ1 level is strong,b no plausible
confounders, consistent and direct
evidence
þ2 levels if very strong,c no major threats
to validity and direct evidence
Other
þ1 level if evidence of a dose-response
gradient
þ1 level if all residual confounders would
have reduced the observed effect
High
Moderate
Low
Very low
GRADE, grading of recommendations assessment, development, and evaluation; RR, relative risk.
aThe highest possible grade is “high” and the lowest possible grade is “very low.”
bStrong evidence of association is deﬁned as “signiﬁcant RR of > 2 (< 0.5)” based on consistent evidence from two or more observational studies, with no plausible
confounders.
cVery strong evidence of association is deﬁned as “signiﬁcant RR of > 5 (< 0.2)” based on direct evidence with no major threats to validity.
Modiﬁed with permission from Uhlig K, Macleod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement
from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;70:2058–2065.171
methodo log i ca l approach www.kisupplements.orgdiscussion on grading of the quality of evidence was led by the
ERT, and the discussion regarding the strength of the rec-
ommendations was led by the Work Group Chairs.
Grading the quality of evidence for each outcome
The ‘quality of a body of evidence’ refers to the extent to
which our conﬁdence in an estimate of effect is sufﬁcient to
support a particular recommendation. Following GRADE, the
quality of a body of evidence pertaining to a particular
outcome of interest is initially categorized on the basis of
study design. For questions of interventions, the initial quality
grade is “high” if the body of evidence consists of RCTs, “low”
if it consists of observational studies, or “very low” if it
consists of studies of other study designs. For questions of
interventions, the Work Group graded only RCTs. The grade
for the quality of evidence for each intervention–outcome
pair was then decreased if there were serious limitations to the
methodological quality of the aggregate of studies; if there
were important inconsistencies in the results across studies; if
there was uncertainty about the directness of evidence
including a limited applicability of ﬁndings to the population
of interest; if the data were imprecise or sparse; or if there was
thought to be a high likelihood of bias. The ﬁnal grade for the
quality of evidence for an intervention–outcome pair could be
1 of the following 4 grades: “high,” “moderate,” “low,” or
“very low” (Table 4).
Grading the overall quality of evidence
The quality of the overall body of evidence was then deter-
mined on the basis of the quality grades for all outcomes of
interest, taking into account explicit judgments about the
relative importance of each outcome. The resulting 4 ﬁnal
categories for the quality of overall evidencewere A, B, C, andD
(Table 5). This grade for overall evidence is indicated behind46the strength of recommendations. The summary of the overall
quality of evidence across all outcomes proved to be very
complex. Thus, as an interim step, the evidence proﬁles
recorded the quality of evidence for each of 3 outcome cate-
gories: patient-centered outcomes, other bone and vascular
surrogate outcomes, and laboratory outcomes. The overall
quality of evidence was determined by the Work Group and is
based on an overall assessment of the evidence. It reﬂects that,
for most interventions and tests, there is no high-quality evi-
dence for net beneﬁt in terms of patient-centered outcomes.
Assessment of the net health beneﬁt across all important
clinical outcomes
Net health beneﬁt was determined on the basis of the antic-
ipated balance of beneﬁts and harm across all clinically
important outcomes. The assessment of net health beneﬁt by
the Work Group and ERT is summarized in one of the
following statements: (i) There is net beneﬁt from interven-
tion when beneﬁts outweigh harm; (ii) there is no net beneﬁt;
(iii) there are trade-offs between beneﬁts and harm when
harm does not altogether offset beneﬁts but requires
consideration in decision making; or (iv) uncertainty remains
regarding net beneﬁt (Table 6).
Grading the recommendations
The “strength of a recommendation” indicates the extent to
which one can be conﬁdent that adherence to the recom-
mendation will do more good than harm. The strength of a
recommendation is graded as Level 1 or Level 2.173 Table 7
shows the nomenclature for grading the strength of a
recommendation and the implications of each level for pa-
tients, clinicians, and policy makers. Recommendations can
be for or against doing something. Table 8 shows that the
strength of a recommendation is determined not just by theKidney International Supplements (2017) 7, 1–59
Table 5 | Final grade for overall quality of evidence
Grade Quality of evidence Meaning
A High We are conﬁdent that the true effect lies
close to that of the estimate of the effect.
B Moderate The true effect is likely to be close to the
estimate of the effect, but there is a
possibility that it is substantially different.
C Low The true effect may be substantially
different from the estimate of the effect.
D Very low The estimate of effect is very uncertain,
and often will be far from the truth.
Table 6 | Balance of beneﬁts and harms
When there was evidence to determine the balance of medical beneﬁts
and harm of an intervention to a patient, conclusions were categorized
as follows:
Net beneﬁts The intervention clearly does more good than
harm.
Trade-offs There are important trade-offs between the
beneﬁts and harm.
Uncertain trade-offs It is not clear whether the intervention does
more good than harm.
No net beneﬁts The intervention clearly does not do more
good than harm.
Table 8 | Determinants of strength of recommendation
Factor Comment
Balance between desirable
and undesirable effects
The larger the difference between the
desirable and undesirable effects, the more
likely a strong recommendation is
warranted. The narrower the gradient, the
more likely a weak recommendation is
warranted.
Quality of the evidence The higher the quality of evidence, the
more likely a strong recommendation is
warranted.
Values and preferences The more variability in values and
preferences, or the more uncertainty in
values and preferences, the more likely a
weak recommendation is warranted.
Costs (resource allocation) The higher the costs of an intervention—
that is, the more resources consumed—the
less likely a strong recommendation is
warranted.
www.kisupplements.org me thodo log i ca l app roachquality of evidence, but also by other, often complex judg-
ments regarding the size of the net medical beneﬁt, values and
preferences, and costs.
Ungraded statements
The Work Group felt that having a category that allows it to
issue general advice would be useful. For this purpose, the
Work Group chose the category of a recommendation that
was not graded. Typically, this type of ungraded statement
met the following criteria: it provides guidance on the basis of
common sense; it provides reminders of the obvious; and it isTable 7 | Implications of the strength of a recommendation
Grade Patients
Level 1:
“We recommend”
Most people in your situation would
want the recommended course of
action, and only a small proportion
would not.
Most patie
recommen
Level 2:
“We suggest”
The majority of people in your situation
would want the recommended course
of action, but many would not.
Different c
for differe
needs hel
decision c
values and
Kidney International Supplements (2017) 7, 1–59not sufﬁciently speciﬁc to allow an application of evidence to
the issue, and therefore it is not based on a systematic review.
Common examples include recommendations regarding the
frequency of testing, referral to specialists, and routine
medical care. The ERT and Work Group strove to minimize
the use of ungraded recommendations.
Limitations of approach
Although the literature searches were intended to be
comprehensive, they were not exhaustive. MEDLINE and
Cochrane CENTRAL were the only databases searched, and
the search was limited to English language publications. Hand
searches of journals were not performed, and review articles
and textbook chapters were not systematically searched.
However, Work Group members did identify additional or
new studies for consideration.
Nonrandomized studies were not systematically reviewed
for studies of interventions. The ERT and Work Group re-
sources were devoted to review of randomized trials, as theseImplications
Clinicians Policy
nts should receive the
ded course of action.
The recommendation can be evaluated
as a candidate for developing a policy
or a performance measure.
hoices will be appropriate
nt patients. Each patient
p to arrive at a management
onsistent with her or his
preferences.
The recommendation is likely to require
substantial debate and involvement of
stakeholders before policy can be
determined.
47
methodo log i ca l approach www.kisupplements.orgwere deemed most likely to provide data to support treatment
recommendations with higher-quality evidence.
Evidence for patient-relevant clinical outcomes was low.
Usually, low-quality evidence required a substantial use of
expert judgment in deriving a recommendation from the
evidence reviewed.
Formulation and vetting of recommendations
Recommendations were drafted to be clear and actionable,
and the wording also considered the ability of concepts to be
translated accurately into other languages. The ﬁnal wording
of recommendations and corresponding grades for the
strength of the recommendations and the quality of evidence
were voted upon by the Work Group and required a majority
to be accepted.48The process of peer review included an external review by
the public to ensure widespread input from numerous
stakeholders, including patients, experts, and industry and
national organizations.
Format for chapters
Each chapter contains one or more speciﬁc recommenda-
tions. Within each recommendation, the strength of the
recommendation is indicated as level 1 or level 2, and the
quality of the overall supporting evidence is shown as A, B,
C, or D. The recommendations are followed by a section
that describes the body of evidence and rationale for the
recommendations. In relevant sections, research recom-
mendations suggest future research to resolve current
uncertainties.Kidney International Supplements (2017) 7, 1–59
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